Page last updated: 2024-08-21

alpha-aminopyridine and Breast Cancer

alpha-aminopyridine has been researched along with Breast Cancer in 367 studies

Research

Studies (367)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (0.27)29.6817
2010's165 (44.96)24.3611
2020's201 (54.77)2.80

Authors

AuthorsStudies
Babbar, N; Bardia, A; Campos-Gomez, S; Chow, L; Colleoni, M; Franke, F; Harbeck, N; Hurvitz, S; Im, SA; Jung, KH; Lee, KS; Lu, YS; Rodriguez Lorenc, K; Sohn, J; Solovieff, N; Su, F; Taran, T; Tripathy, D; Vázquez, RV1
Carayannopoulos, L; Cheng, Y; Li, Y; Reyes, J; Tong, Z; Wang, X; Zhou, S1
Barsky, AR; Clark, A; Dastgheyb, S; Dreyfuss, AD; Freedman, GM; Kim, KN; Shah, P; Taunk, NK1
Andersson, M; André, V; Barriga, S; Cortés, J; Del Mastro, L; Fasching, PA; Forrester, T; Goetz, MP; Guarneri, V; Hamilton, E; Harbeck, N; Hegg, R; Huang, CS; Jaliffe, GG; Johnston, SRD; Kreipe, H; Martin, M; Munoz, M; Nabinger, SC; O'Shaughnessy, J; Rastogi, P; Rugo, HS; San Antonio, B; Senkus, E; Shahir, A; Shao, ZM; Sherwood, S; Sohn, J; Steger, GG; Tamura, K; Testa, L; Toi, M; Tolaney, SM; Tryakin, A; Wei, R1
Araki, K; Hamada, M; Ikeda, T; Minamoto, K1
Goetz, MP; Kawaguchi, T; Mori, J; Takahashi, M; Tanizawa, Y; Toi, M; Tokunaga, E; van der Walt, JS1
Cheng, MY; Gao, HF; Ji, F; Li, JQ; Niu, G; Wang, K; Yang, CQ; Yang, M; Zhang, JS; Zhang, LL; Zhang, QZ; Zhu, T1
Alberti, M; Basile, D; Buzzo, M; Canil, G; Gagno, S; Gerratana, L; Guardascione, M; Iacuzzi, V; Montico, M; Orleni, M; Pelizzari, G; Poetto, AS; Posocco, B; Puglisi, F; Toffoli, G; Zanchetta, M1
Lagampan, C; Parinyanitikul, N; Poovorawan, N1
Harbeck, N; Johnston, S; O'Shaughnessy, J; Rastogi, P; Shahir, A1
Anand, K; Düster, R; Geyer, M; Gray, NS; Kaltheuner, IH; Moecking, J; Wang, J1
Bardia, A; Foukakis, T; Matikas, A; Spring, L1
Freedman, RA; Giordano, SH; Somerfield, MR1
Chen, Y; Kawaguchi, T; Masuda, N; Ohno, S; Saji, S1
Burstein, HJ; Curigliano, G; Hamilton, EP; Hurvitz, SA; Krop, IE; Lin, NU; Rugo, HS; Schnitt, SJ; Tarantino, P; Tolaney, SM; Winer, EP1
Brucker, S; Busse, A; Decker, T; Fasching, P; Fehm, T; Gjerga, E; Grunert, C; Hennig, S; Janni, W; Keilholz, L; Keller, U; Kümmel, S; Lüftner, D; Na, IK; Peuker, CA; Schaper, S; Schneeweiss, A; Schuler, M; Yaghobramzi, S1
Babu, KG; Bardia, A; Campos-Gomez, S; Cardoso, F; Chakravartty, A; Chow, L; Colleoni, M; De Laurentiis, M; El-Saghir, N; Franke, F; Gasch, C; Harbeck, N; Hurvitz, S; Im, SA; Im, YH; Ji, Y; Jung, KH; Kuemmel, S; Lee, KS; Lu, YS; O'Regan, R; Sohn, J; Solovieff, N; Tripathy, D; Villanueva Vazquez, R; Wang, C; Wang, Y; Wheatley-Price, P1
Banala, VT; Gautam, S; Gupta, A; Marwaha, D; Mishra, PR; Mitra, K; Mittapelly, N; Rai, N; Sharma, M; Singh, N; Urandur, S1
Asghar, US; Kanani, R; Mittnacht, S; Roylance, R1
Beck, JT; Chan, A; Chandiwana, D; De Laurentiis, M; Delea, TE; Fasching, PA; Im, SA; Jerusalem, G; Lanoue, B; Lonshteyn, A; Martin, M; Neven, P; Nusch, A1
Amiri-Kordestani, L; Beaver, JA; Bloomquist, E; Ghosh, S; Kalavar, S; Mixter, BD; Mulkey, F; Osgood, C; Pazdur, R; Philip, R; Pierce, WF; Rizvi, F; Roy, A; Royce, M; Tang, S1
Kinoshita, T; Sakurada, A; Sakurai, T; Seki, H; Shimizu, K1
Grischke, EM; Jansen, VM; Litchfield, LM; Llombart-Cussac, A; Neven, P; Sledge, GW; Sohn, J; Soliman, H; Toi, M; Tolaney, SM; Wang, H; Wijayawardana, S1
Abdel-Razeq, H; Cardoso, F; Cottu, P; De Laurentiis, M; Marchetti, P; Martín, M; Menon-Singh, L; Ring, A; Salvador Bofill, J; Wu, J1
Ali, J; Baboota, S; Biswas, L; Sahoo, PK; Sartaj, A; Verma, AK1
Abdel-Rahman, O; de Sousa, MJ; Fazio, N; Gervaso, L; Meneses-Medina, MI; Spada, F1
André, F; Arteaga, CL; Burris, HA; Cameron, DA; Campone, M; Chakravartty, A; Conte, P; Hart, L; Hortobagyi, GN; Janni, W; Le Gac, F; O'Shaughnessy, J; Petrakova, K; Serra, P; Sonke, GS; Stemmer, SM; Taran, T; Winer, EP; Yap, YS; Zarate, JP1
Denaro, V; Francesco, P; Iuliani, M; Longo, UG; Napolitano, A; Orsaria, P; Ribelli, G; Santini, D; Simonetti, S; Tonini, G; Vincenzi, B1
Fleming, GF; Francis, PA; Pagani, O; Regan, MM; Walley, BA1
Lavenia, G; Martorana, F; Prestifilippo, A; Ricciardi, GR; Rossello, R; Sanò, MV; Sava, S; Vigneri, P1
Blancas, I; Boyle, F; Broom, R; Brown, J; Campone, M; Gumus, M; Hulstijn, M; Im, YH; Johnston, SRD; O'Shaughnessy, J; Rastogi, P; Reinisch, M; Rugo, HS; San Antonio, B; Shahir, A; Song, C; Toi, M; Tolaney, SM; Wei, R; Yamashita, T; Zagouri, F; Zimmermann, A1
Jacobson, A1
Freedman, RA; Giordano, SH; Graff, SL; Somerfield, MR; Telli, ML; Wolff, AC1
Curigliano, G; Jin, Q; King, TA; Mittendorf, EA; Tarantino, P; Tolaney, SM1
Çelik, H; Çil, T; Duman, BB; Erçolak, V; Eser, K; İnal, A; Kesen, O; Köşeci, T; Önder, AH; Öztürk, B; Sezer, E1
Ando, H; Ebi, H; Fukushima, S; Hashimoto, N; Irie, K; Iwata, H; Maeda, A; Matsuzaki, M; Morishige, JI; Okada, A; Sawaki, M1
Dixit, J; Gupta, D; Gupta, N; Gupta, S; Jyani, G; Kalaiyarasi, JP; Kataki, A; Krishnamurthy, MN; Kumar, L; Malhotra, P; Malik, PS; Mathew, A; Mehra, N; Prinja, S; Rajsekhar, K; Roy, PS; Singh, A1
Cuyun Carter, G; Gathirua-Mwangi, WG; Huang, YJ; Morato Guimaraes, C; Nash Smyth, E; Price, GL; Rajkumar, J; Ryan, P; Rybowski, S; Sheffield, KM; Sudharshan, L1
Ateş, Ö; Karaçin, C; Özdoğan, S; Şeyran, E; Türkel, A; Yekedüz, E1
Beniak, J; Borstnar, S; Gal-Yam, EN; Kudela, P; Palacova, M; Papazisis, K; Rubovszky, G; Timcheva, C; Łacko, A1
Higashi, T; Mase, K; Mizutani, M; Moriya, T; Ozawa, K; Takagi, S; Takei, S; Takeshita, A; Yokoyama, M1
Adamchuk, H; Dakhil, S; Denduluri, N; Fernandez, MM; Forrester, T; Garcia-Saenz, JA; Grecea, D; Headley, D; Hegg, R; Johnston, SRD; Kim, SB; Lacko, A; Martin, M; Okera, M; Oksuzoglu, B; Ouyang, Q; Papazisis, K; Reeves, J; Schenker, M; Shimizu, C; Testa, L; Wei, R; Zimmermann, A1
Cushman, J; Hamilton, E; Moore, H; Sammons, S1
Aske, J; De, P; Dey, N; Koirala, N1
Al-Samkari, H; Shatzel, JJ; Wander, SA; Watson, NW1
Baquero, C; Bian, H; de Dios, A; Du, J; Ganado, MP; Lallena, MJ; Marugan, C; Mur, C; Puig, O; Torres-Guzmán, R; Yang, Y; Zeng, Y1
Chen, SC; Chen, Y; Cortes, J; Hamilton, E; Hegg, R; Huober, J; Jerusalem, G; Manikhas, A; Martin, M; Ozyilkan, O; Petrakova, K; Zhang, W1
Boyle, F; Chapman, SC; Chen, Y; Ezquerra, MB; Gable, JC; Gainford, MC; Goksu, SS; Hossain, AM; Lim, E; Loi, S; Okera, M; Price, GL; van Hal, G1
Chao, TC; Huang, CC; Lai, JI; Lin, CY; Liu, CY; Tseng, LM; Yu, CJ1
Goel, S; Litchfield, LM; Morato Guimaraes, C; O'Brien, N; O'Dea, D; Slamon, DJ; Wander, SA1
Arumí, M; Ciruelos, E; Falato, C; Ferrer, N; Gavilá, J; Gil-Gil, M; Gómez, G; González-Santiago, S; Hernando, C; Izarzugaza, Y; Montaño, A; Muñoz, M; Najera-Zuloaga, J; Paré, L; Pascual, T; Prat, A; Saura, C; Villacampa, G; Villagrasa, P1
Agrawal, KU; Barke, MR; Shields, CL1
Abbinante, G; Arcara, C; Bisagni, G; Coltelli, L; Faggioni, G; Geuna, E; Grasso, D; Gunnellini, M; Livi, L; Moretti, G; Ragni, F; Rinaldi, G; Sanna, G; Scotti, V; Staropoli, N; Vannini, L; Verderame, F1
Haddad, N; Huang, CS; Im, YH; Sakaguchi, S; Sledge, GW; Sohn, J; Toi, M; van Hal, G; Zhang, W1
Johnston, SRD; Martin, M; Wei, RJ1
Sun, R; Wei, LJ1
Asano, Y; Kashiwagi, S; Morisaki, T; Nakamura, Y; Nakatsukasa, H; Noda, S; Takahashi, K; Takahashi, M; Takashima, T1
Atake, Y; Bun, A; Fujimoto, Y; Fukui, R; Hattori, A; Higuchi, T; Imamura, M; Kanaoka, H; Miyoshi, Y; Murase, K; Nagahashi, M; Natori, K; Ozawa, H; Takatsuka, Y1
Alvarez Lopez, IM; Anton Torres, A; Barnadas Molins, A; Bellet Ezquerra, M; Cantos Sanchez de Ibargüen, B; Ciruelos Gil, EM; de Casa, S; De la Cruz Merino, L; De la Haba-Rodriguez, J; de Toro Salas, R; Delgado Mingorance, JI; Diaz Fernandez, N; Galve Calvo, E; Gavila Gregori, J; Gimeno, A; Gonzalez-Santiago, S; Hernando Melia, C; Jiménez-Rodriguez, B; Martin, M; Martínez Jañez, N; Moreno Anton, F; Quiroga Garcia, V; Rodriguez Sanchez, CA; Salvador Bofill, J; Vicente Rubio, E; Vidal, M; Villanueva Vazquez, R1
Acar, Ö; Aksoy, S; Aykan, MB; Çelebi, A; Chalabiyev, E; Doğan, A; Dursun, B; Erdoğan, AP; Günenç, D; Güven, DC; Hacıbekiroğlu, İ; İnanç, M; Kahraman, S; Kaman, Ö; Keskinkılıç, M; Kılıçkap, S; Melisa Celayir, Ö; Mutlu, E; Ön, S; Özen, M; Vedat Bayoğlu, İ; Yalçın, Ş; Yavuzşen, T; Yıldırım, HÇ1
Angelini, L; Bargagna, I; Biondani, P; Crucitta, S; D'Onofrio, R; Danesi, R; De Giorgi, U; Del Re, M; Fogli, S; Fontana, A; Giontella, E; Livi, L; Lorenzini, G; Meattini, I; Mongillo, M; Natalizio, S; Omarini, C; Palleschi, M; Porta, C; Stucci, S1
Boyle, F; Grimes, BR; Im, YH; Jiang, Z; Johnston, SRD; Molthrop, D; Nabinger, SC; Reinisch, M; Sapunar, F; Toi, M; Wei, R1
Baba, K; Funasaka, C; Harano, K; Hosono, A; Kawamoto, M; Kawasaki, T; Kondoh, C; Kusuhara, S; Mamishin, K; Matsubara, N; Mukohara, T; Naito, Y; Nakajima, H; Nakao, T; Sasaki, T1
Arpino, G; Barchiesi, G; De Laurentiis, M; Del Mastro, L; Di Lauro, V; Fontanella, C; Giuliano, M; Martorana, F; Muratore, M; Puglisi, F; Zucchini, G1
Araz, M; Artaç, M; Çağlayan, D; Eryılmaz, MK; Geredeli, Ç; Göksu, SS; Koçak, MZ; Tatlı, AM1
Ge, R; Jiang, ZF; Wang, BY1
Habler, K; Kalla, AS; Rychlik, M; Teupser, D; Vogeser, M1
Al-Samkari, H; Shatzel, JJ; Watson, NW1
Araz, M; Artaç, M; Er, MM; Eryılmaz, MK; Hendem, E1
Chakraborty, A; Ji, Y; Miller, M; Quinlan, M; Serra, P; Wang, Y; Yartsev, V1
Blair, HA; Fung, S1
Caruso, M; Gebbia, V; Giotta, F; Martorana, F; Piazza, D; Sanò, MV; Spada, M; Valerio, MR; Vigneri, P1
Iwata, H; Nozawa, K; Sawaki, M1
André, V; Johnston, SRD1
Ahmadu, C; Armstrong, N; Coughlan, D; Duffy, S; Kernohan, A; Kleijnen, J; McDermott, K; O'Meara, S; Orozco Leal, G; Robinson, T; Vale, L1
Coutinho, A; Cui, ZL; Karuturi, M; Lokhandwala, T; Lunacsek, O; Ring, A; Rybowski, S; Sapunar, F; Sheffield, KM; Smyth, EN; Willey, J1
Allegrini, G; Arpino, G; Benelli, M; Bianchi, GV; Bianchini, G; Caputo, R; Castelletti, D; Cazzaniga, ME; Colleoni, M; De Laurentiis, M; Del Mastro, L; Di Marino, M; Guarneri, V; Malorni, L; Montemurro, F; Orditura, M; Paris, I; Puglisi, F; Tamberi, S; Zamagni, C; Zambelli, A1
Bruno, S; Fancellu, A; Fedele, P; Giuliani, F; Guarini, C; Iaia, ML; Laface, C; Maselli, FM; Melaccio, A; Perrone, M; Sanna, V; Santoro, AN1
Amiri-Kordestani, L; Bloomquist, E; Mulkey, F; Osgood, C; Royce, M1
Gebbia, V; Martorana, F; Sanò, MV; Valerio, MR; Vigneri, P1
Harbeck, N; Johnston, SRD; Martin, M; O'Shaughnessy, J; Rastogi, P; Tolaney, SM1
Goldstein, DA; Gyawali, B; Meirson, T; Tannock, IF1
Fakhouri, W; Faris, LH; Haro, JM; Kawaguchi, T; Novick, D; Nozawa, K; Onishi, M; Ozaki, Y; Takano, T; Tanizawa, Y; Terada, M; Tsurutani, J1
Aguiar-Bujanda, D; Álvarez, I; Andrés, R; Antón, A; Bermejo, B; Carrasco, E; Chacón, JI; Cruz, J; Guerrero, Á; Jara, C; Lopez-Tarruella, S; Martín, M; Martínez, P; Miralles, JJ; Muñoz, M; Polonio, Ó; Ramos, M; Rodríguez-Lescure, Á; Ruiz-Borrego, M; Santaballa, A; Servitja, S1
Bouganim, N; Brezden-Masley, C; Edwards, S; Gelmon, K; Henning, JW; Hilton, JF; Jerzak, KJ; Sehdev, S1
Barrios, C; Cameron, D; Emde, A; Gnant, M; Janni, W; Johnston, S; Martin, M; Neven, P; Srock, S1
Hashishita, H; Kuwahara, S; Maeda, H; Takada, S; Takahashi, M; Tomioka, N; Umehara, K; Watanabe, K; Yamamoto, M1
Clarke, R; Goetz, MP; O'Sullivan, CC; Robertson, J1
de Leng, WWJ; de Vos, FYFL; de Wit, GF; Espinoza, D; Gelderblom, H; Geurts, BS; Hoes, LR; Jansen, AML; Lee, CK; Leek, LVM; Lin, FP; Looze, EJ; Roepman, P; Sebastian, L; Simes, RJ; Sjoquist, KM; Thavaneswaran, S; Thomas, DM; van Berge Henegouwen, JM; van der Noort, V; van der Wijngaart, H; van Herpen, CML; Verheul, HMW; Voest, EE; Zeverijn, LJ1
Chakraborty, A; Chakravartty, A; Darstein, C; Ho, YY; Ji, Y; Quinlan, M; Yang, S; Zarate, JP1
Aruga, T; Babbar, N; Balbin, OA; Chiu, J; Ishikawa, T; Joshi, M; Masuda, N; Su, F; Yap, YS; Zarate, JP1
Hayashi, M; Hirata, A; Kimura, K; Morita, S; Takashima, Y; Terasawa, R1
André, F; Arteaga, CL; Babbar, N; Bardia, A; Chia, S; Hortobagyi, G; Lteif, A; Lu, YS; Neven, P; Slamon, D; Solovieff, N; Su, F; Taran, T; Tripathy, D1
Bauer, S; Decker, T; Denkert, C; Filmann, N; Hirmas, N; Loibl, S; Lorenz, R; Lübbe, K; Lüdtke-Heckenkamp, K; Melnichuk, L; Müller, V; Mundhenke, C; Schmidt, M; Seropian, P; Thill, M; Zahm, DM; Zahn, MO1
Aogi, K; Futamura, M; Hosonaga, M; Imamura, CK; Iwasa, T; Iwata, H; Kawabata, H; Masuda, J; Masuda, N; Matsumoto, K; Miura, S; Mukohara, T; Sakai, H; Takahashi, M; Takano, T; Tanabe, Y; Tomioka, N; Tsurutani, J; Yamochi, T; Yasojima, H; Yoshimura, K1
Chang, CM; Lam, HYP1
Ahmed, KA; Arrington, JA; Etame, AB; Figura, NB; Forsyth, PA; Han, HS; Liu, JK; Mohammadi, H; Oliver, DE; Potluri, TK; Robinson, TJ; Sahebjam, S; Soliman, H; Tran, ND; Yu, HM1
Han, X; Lu, C; Lv, S; Qiao, P; Ren, C; Sun, Y; Wang, D; Wang, L; Yang, T; Yu, Z1
Johnston, SR; Lee, KA; Shepherd, ST1
de Dios, A; Lallena, MJ; Sánchez-Martínez, C; Sanfeliciano, SG1
Ay, B; Bozkaya, Y1
Arpino, G; Bachelot, T; Cristofanilli, M; De Laurentiis, M; De Placido, P; De Placido, S; Del Mastro, L; Generali, D; Giordano, A; Giuliano, M; Jerusalem, G; Milani, M; Pistilli, B; Prat, A; Puglisi, F; Rognoni, C; Schettini, F; Thomas, G; Venturini, S1
Grellety, T; Meynard, L1
Buchanan, S; Enatsu, S; Hayashi, S; Maeda, K; Sakaguchi, S; Sato, A; Tamaki, C1
Barriga, S; Burdaeva, O; Conte, P; Frenzel, M; Grischke, EM; Hurt, K; Inoue, K; Johnston, S; Kaufman, PA; Koh, H; Llombart-Cussac, A; Lu, Y; Masuda, N; Neven, P; Okera, M; Pivot, X; Sledge, GW; Sohn, J; Toi, M1
Stirrups, R1
Killock, D1
Aoun, M; Assi, T; Awada, A; Farhat, F; Kanj, A; Kattan, J; Tarabaih, M1
Melegari, E; Palleschi, M; Rocca, A1
Im, SA; Lu, YS; Tripathy, D1
Tamura, K1
Lu, H; Luo, Q; Wang, Y; Zhou, X1
Kiely, BE; Mok, K; Moylan, E; Nguyen, R; Wilson, BE1
Beck, JT; Bianchi, GV; Chakravartty, A; Chia, S; De la Cruz-Merino, L; De Laurentiis, M; Esteva, FJ; Fasching, PA; Im, SA; Jerusalem, G; Martín, M; Neven, P; Nusch, A; Petrakova, K; Pivot, X; Rodriguez-Lorenc, K; Slamon, DJ; Sondhi, M; Sonke, GS; Taran, T; Wang, Y1
Cristofanilli, M1
El Zein, N; Hachem, R; Hilal, G; Raad, I; Sarkis, R; Tahtouh, R; Wardi, L1
Bentham, RB; Bianchi, K; Carter, E; Dalli, J; Godinho, SA; Grose, R; Hodivala-Dilke, K; Holdsworth, J; Ironside, A; Jones, L; Jones, W; Mataloni, I; Moreno Béjar, R; Szabadkai, G; Uhlik, L; Wilcz-Villega, E; Xu, R1
Dunst, J; Fabian, A; Krug, D1
Bascialla, L; De Giorgi, A; Gallerani, E; Giaquinto, A; Grigioni, E; Gueli, R; Marrazzo, C; Nigro, O; Pinotti, G; Vallini, I1
Andre, V; Carter, GC; Grischke, EM; Kaufman, PA; Neven, P; Price, GL; Shekarriz, S; Sledge, GW; Sohn, J; Stoffregen, C; Toi, M1
André, T; Bay, JO; Bouleuc, C; Hervé, L; Magné, N; Penel, N; Rodrigues, M; Sabatier, R; Thiery-Vuillemin, A; Wislez, M1
Buisseret, L; de Azambuja, E; Eiger, D; Nogueira, MS; Pondé, NF; Wagner, M1
Figlia, G; Kaya, O; Martin-Villalba, A; Romero-Pozuelo, J; Teleman, AA1
André, F; Catron, K; Chan, A; Chapman, SC; Gainford, MC; Goel, S; Hilton, JF; Im, SA; Johnston, SR; Kim, SB; Price, GL; Ricci, F; Tolaney, SM; Troso-Sandoval, TA; Wardley, AM; Yang, Z; Zambelli, S1
Battisti, NML; Ring, A1
Ball, S; Sultan, A; Swarup, S; Thein, KZ1
O'Shaughnessy, J1
Beitsch, P; Patel, R; Whitworth, P1
Briceño-Casado, MDP; Fénix-Caballero, S; Gil-Sierra, MD1
Kim, DH; Sun, R; Wei, LJ1
Frenzel, M; Sledge, GW1
Hindié, E1
Jerusalem, G; Slamon, DJ1
Barbolini, M; Dominici, M; Molinaro, E; Omarini, C; Piacentini, F1
Andre, V; Gainford, MC; Goetz, MP; Huober, J; Johnston, S; Martin, M; Park, IH; Price, GL; Shekarriz, S; Stoffregen, C; Toi, M; Tokunaga, E1
Firenze, A; Gebbia, V; Valerio, MR; Vigneri, P1
Aruga, T; Chiu, J; Gazdoiu, M; Gounaris, I; Han, Y; Ishikawa, T; Ito, Y; Ji, Y; Kim, SJ; Masuda, N; Saeki, T; Saito, M; Su, F; Toyama, T; Yap, YS1
Aquilano, M; Cerbai, C; Desideri, I; Dominici, L; Livi, L; Marinko, T; Meattini, I; Orazem, M; Ratosa, I; Ribnikar, D; Scoccimarro, E; Steinacher, M1
Chigutsa, E; Kambhampati, SRP; Karen Sykes, A; Posada, MM; Turner, PK; van der Walt, JS1
Anders, CK; Awada, A; Bachelot, T; Bear, M; Chan, A; Chapman, SC; Chen, Y; Conte, P; Diéras, V; Kabos, P; Le Rhun, E; Lin, NU; Sahebjam, S; Tolaney, SM; Yang, Z; Yardley, D1
Abdelhady, AM; Ji, Y; Rodriguez Lorenc, K; Samant, TS; Yang, S1
Guarino, S; Massaioli, C; Stocchi, L1
Chang, YC; Chao, TY; Chen, SC; Chitapanarux, I; Gao, M; Jung, KH; Kim, JH; Lee, KS; Liu, CT; Lu, YS; Park, YH; Shotelersuk, K; Slader, C; Sohn, J; Tseng, LM; Valenti, R; Yang, Y1
Ameye, L; Awada, A; Azambuja, E; Brandão, M; Caparica, R; De Angelis, C; Desmedt, C; Di Cosimo, S; Eiger, D; Franzoi, MA; Kotecki, N; Lambertini, M; Piccart, M; Ponde, N1
Atienza, M; Cassinello, A; Ciruelos, E; Garcia-Saenz, JA; Llombart, A; Manso, L; Martin, M; Ringeisen, F1
Feng, X; Han, H; Sun, T; Xu, J; Zhou, W1
Alongi, F; Buglione, M; Costantino, G; Figlia, V; Guerini, AE; Maddalo, M; Magrini, SM; Pasinetti, N; Pedersini, R; Pedretti, S; Pegurri, L; Peretto, G; Salah, E; Simoncini, EL; Triggiani, L; Vassalli, L1
Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y1
Chang, A; Cheng, D; Huang, S; Liu, AT; Sun, P; Tan, X; Wang, G; Wang, J; Wang, Q; Wu, D; Xiang, R; Yang, S; Zhao, S1
Ando, H; Ebi, H; Fukushima, S; Hashimoto, N; Irie, K; Iwata, H; Kajita, M; Maeda, A; Okada, A; Sawaki, M1
Kishino, E; Koike, Y; Kurebayashi, J; Ogata, R; Saitoh, W1
Amir, E; Desnoyers, A; Kumar, V; Nadler, MB; Saleh, R1
Abdelhady, AM; Bachelot, T; Calvo, E; Fasolo, A; Forero-Torres, A; Hamilton, E; Im, YH; Lee, SC; Lu, YS; Maur, M; Nardi, L; Ruan, S; Stammberger, U; Tiedt, R; Tolaney, SM1
Wolff, AC1
Boyle, F; Campone, M; Cicin, I; Cortés, J; Cox, J; Frenzel, M; Guarneri, V; Hamilton, E; Harbeck, N; Headley, D; Hegg, R; Hulstijn, M; Huober, J; Johnston, SRD; Martin, M; Martinez Rodriguez, JL; Neven, P; O'Shaughnessy, J; Okada, M; Rastogi, P; San Antonio, B; Shao, ZM; Smith, IC; Sohn, J; Toi, M; Tolaney, SM; Wardley, A; Wei, R; Zhang, QY1
Andre, VAM; Barriga, S; Cox, J; García-Sáenz, JA; Goetz, M; Huober, J; Masuda, N; Rugo, HS; Sohn, JH1
Beijnen, JH; Groenland, SL; Huitema, ADR; Martínez-Chávez, A; Schinkel, AH; Steeghs, N; van Dongen, MGJ1
Awada, A; El Hachem, G; Gombos, A1
Beck, JT; Bianchi, GV; Chan, A; Chandiwana, D; De Laurentiis, M; Esteva, FJ; Fasching, PA; Jerusalem, G; Lanoue, B; Martin, M; Neven, P; Nusch, A; Pivot, X; Ridolfi, A; Rodriguez Lorenc, K; Wang, Y1
Jerusalem, G; Neven, P; Sonke, GS1
Aziz, MIA; Lee, SC; Loke, L; Ng, K; Pearce, F1
de Luna, A; Fuentes-Antrás, J; García-Sáenz, JÁ; López de Sá, A; Moreno, F; Ocaña, A1
Alexandre, J; Chretien, B; Da Silva, A; Emile, G1
Clark, AS; DeMichele, A; Makhlin, I1
Bear, MM; Chapman, SC; Chen, SC; Cortes, J; Hamilton, E; Hardebeck, MC; Hegg, R; Huober, J; Jerusalem, G; Johnston, EL; Lu, Y; Manikhas, A; Martin, M; Ozyilkan, O; Petrakova, K1
Díaz Almirón, M; García-Trevijano Cabetas, M; Herrero Ambrosio, A; Jiménez Nácher, I; Lucena Martínez, P; Zamora Auñón, P1
Alhudaithi, SS; Almuqbil, RM; Bielski, ER; Bos, PD; da Rocha, SRP; Du, W; Sunbul, FS; Zhang, H1
Asai, S; Hirashima, T; Hozaka, Y; Kijima, Y; Nohata, N; Ohtsuka, T; Okada, R; Seki, N; Shinden, Y; Tanaka, T; Toda, H1
Curigliano, G1
Alfonso, F; Alvarado-Casas, T; Rivero, F; Salamanca, J; Vera, A1
Björnsson, ES; Finnsdottir, S; Sverrisdottir, A1
Canova, C; Klausner, G; Troussier, I1
Harbeck, N1
Cardoso, F; Di Cosimo, S; Porcu, L1
Jian, L; Lian, S; Liu, M; Liu, N; Wang, S; Zhang, G; Zhang, Y; Zhao, Q1
Ait-Oudhia, S; Franco, YL; Mody, H; Perez, L; Ramakrishnan, V; Vaidya, TR1
André, VAM; Campone, M; Chouaki, N; Goetz, MP; Grischke, EM; Manso, L; Okera, M; San Antonio, B; Sledge, GW; Toi, M; Wildiers, H1
Printz, C1
Asou, H; Chen, Y; Mori, S; Noma, S; Sakaguchi, S; Taguchi, Y; Takahashi, M; Tomii, K; Tsurutani, J1
Akiyama, Y; Doi, S; Hagihara, K; Matsushita, K; Motoki, Y; Nakaguchi, K; Sakisaka, H1
Ji, Y; Miller, M; Samant, TS; Yang, S1
Bananis, E; Cameron, C; Haltner, A; Hooper, B; Mitra, D; Rugo, HS; Tran, A; Zhan, L1
Agostinetto, E; de Azambuja, E; Debien, V; Lambertini, M; Marta, GN; Piccart-Gebhart, M1
Huang, P; Huang, X; Lin, S; Rao, X; Wang, H; Weng, X; Zeng, D1
André, VAM; Chen, SC; Enatsu, S; Goetz, MP; Hae Park, I; Hardebeck, MC; Im, SA; Inoue, K; Iwata, H; Masuda, N; Sakaguchi, S; Sledge, GW; Sohn, J; Toi, M; Turner, PK1
Ho, YY; Ji, Y; Lu, Y; Yang, S1
Berg, T; Jensen, AB; Kodahl, AR; Kristensen, KB; Thomsen, IMN1
Erdal, GS; Gulturk, I; Ozmen, A; Tacar, SY; Tural, D; Yilmaz, M1
Abuhelwa, AY; Badaoui, S; Hopkins, AM; McKinnon, RA; Modi, ND; Rowland, A; Shankaran, K; Shaw, E; Sorich, MJ1
Badaoui, S; Hopkins, AM; Kichenadasse, G; Rowland, A; Sorich, MJ1
Doerler, M; Gambichler, T; Ocker, L; Stranzenbach, R; Susok, L1
Balakrishna, S; Bowman, L; Cohen, AB; Cuyun Carter, G; Gossai, A; Huang, YJ; Mathur, R; Morato Guimaraes, C; Nash Smyth, E; Rasmussen, E; Rybowski, S; Seidman, AD; Sheffield, KM; Zhu, YE1
Kudo, S; Makino, T; Tanaka, T; Umetsu, R1
Gallagher, P; Haynes, HR; Mohan, V; Mozayani, B1
Chandiwana, D; Delea, TE; Park, J; Stellato, D; Thabane, ME2
Abe, M; Chiba, R; Ishiguro, A; Ito, K; Kato, H; Kubota, R; Matsunami, O; Narita, Y; Ohigashi, A; Tanimoto, A1
Jung, US; Kim, DH; Kim, HS; Kim, MG; Min, KW1
Beck, JT; Chakravartty, A; Chia, S; De la Cruz-Merino, L; De Laurentiis, M; Deore, U; Fasching, PA; Im, S; Jerusalem, G; Ji, Y; Martín, M; Neven, P; Nusch, A; Petrakova, K; Slamon, DJ; Sonke, GS; Taran, T; Valeria Bianchi, G; Wang, C; Zarate, JP1
Cottu, P; Coussy, F; Deluche, E; Ferrero, JM; Ladoire, S; Pistilli, B1
Bardia, A; Burris, HA; Chan, A; Chia, S; Esteva, FJ; Hart, L; Im, SA; Lorenc, KR; Neven, P; Ridolfi, A; Sohn, J; Thaddeus Beck, J; Tripathy, D; Yardley, DA; Zarate, JP1
Adamo, B; Bellet, M; Brasó-Maristany, F; Carey, LA; Chic, N; Ciruelos, E; Cortés, J; Galván, P; Gavilá, J; González-Farré, B; Martínez, D; Martínez-Sáez, O; Muñoz, M; Oliveira, M; Pascual, T; Pernas, S; Perou, CM; Prat, A; Sanfeliu, E; Saura, C; Schettini, F; Soberino, J; Vidal, M1
Besiroglu, M; Gucin, Z; Seker, M; Shbair, AT; Simsek, M; Sucuoglu, Z; Topcu, A; Turk, HM; Yasin, AI; Yurtsever, I1
Akamatsu, H; Arteaga, CL; Brewer, MR; Brown, BP; Chatterjee, S; Hanker, AB; He, J; Jayanthan, HS; Koch, JP; Lalani, AS; Lee, KM; Lin, CC; Marín, A; Meiler, J; Servetto, A; Sheehan, JH; Sudhan, DR; Ye, D1
Bajpai, J; Elamarthi, P; Ghosh, J; Gulia, S; Gupta, S; Kembhavi, Y; Mokal, S; Nandhana, R; Parab, P; Perumal, P; Rath, S1
Abbas, H; Lim, Z; Malik, AA; Oo, ZM1
Burdaeva, O; Conte, P; Grischke, EM; Haddad, N; Hurt, KC; Inoue, K; Johnston, SRD; Kaufman, PA; Koh, H; Llombart-Cussac, A; Lu, Y; Masuda, N; Neven, P; Okera, M; Pivot, X; Sledge, GW; Sohn, J; Toi, M1
Azim, HA; Bofill, JS; Borstnar, S; Campone, M; Chatterjee, S; Ciruelos, E; Cottu, P; De Laurentiis, M; Dent, S; Jacot, W; Lu, J; Martin, M; Menon-Singh, L; Ring, A; Warner, E; Wu, J; Zamagni, C; Zhou, K1
Goetz, MP; Haddad, N; Hurt, KC; Iwata, H; Kaufman, PA; Lu, Y; Neven, P; Rugo, HS; Sledge, GW; Toi, M; Tolaney, SM1
Balbin, A; Cresta, S; Crystal, A; Curigliano, G; De Vita, S; Duhoux, FP; He, W; Huober, J; Jhaveri, K; Ji, Y; Juric, D; Kundamal, N; Layman, RM; Sheng, Q; Takahashi, S; Terret, C; Yap, YS1
Mullard, A1
Blackwell, KL; Sammons, SL; Topping, DL1
Criscitiello, C; Curigliano, G; Esposito, A; Intra, M; Minucci, S1
Syed, YY1
Liu, Q; Mani, S; Pestell, RG; Wu, K; Xu, H; Yu, S; Yuan, X1
Peplow, M1
Arteaga, CL; Awada, A; Baselga, J; Campone, M; Chia, S; Clemons, M; Cortés, J; De Laurentiis, M; Dharan, B; Di Tomaso, E; Hachemi, S; Hurvitz, S; Im, SA; Ito, Y; Iwata, H; Jagiełło-Gruszfeld, A; Jiang, Z; Jonat, W; Massacesi, C; Masuda, N; Pistilli, B; Takahashi, M; Tseng, LM; Urban, P; Vuylsteke, P1
Griggs, JJ; Wolff, AC1
Barriga, S; Bourayou, N; Burdaeva, O; Frenzel, M; Grischke, EM; Inoue, K; Kaufman, PA; Koh, H; Lin, Y; Llombart-Cussac, A; Masuda, N; Neven, P; Okera, M; Pivot, X; Sledge, GW; Smith, IC; Sohn, J; Toi, M1
Carneiro, BA; Costa, R; Costa, RB; Giles, FJ; Gradishar, WJ; Helenowski, I; Kaplan, J; Peterson, J; Talamantes, SM1
Fan, Y; Guo, Q; Huang, Z; Li, Y; Liu, Y; Wang, T; Wang, X; Xiang, R; Xu, G; Yang, S; Zhang, C1
Akıncı, MB; Bilgin, B; Sendur, MAN; Şener Dede, D; Yalçın, B1
Chen, S; Huang, TT; Liu, CY; Petrossian, K; Tseng, LM; Wu, CY1
Bardia, A; Moy, B; Spring, LM; Zangardi, ML1
Kwapisz, D2
Echavarria, I; Jerez, Y; López-Tarruella, S; Márquez-Rodas, I; Martin, M1
Dees, EC; Henderson, GE; Reeder-Hayes, KE; Roberts, MC1
Caponigro, G; Germa, C; Hewes, B; Hirawat, S; Miller, M; Mukhopadhyay, P; Scherer, SJ1
Criscitiello, C; Curigliano, G; Viale, G1
Bardia, A; Blouin, GC; Spring, LM; Zangardi, ML1
Baselga, J; Bermejo, B; de la Pena, L; Denkert, C; Gombos, A; Kümmel, S; Lee, SC; Loi, S; Loibl, S; Lux, M; Michiels, S; Nekljudova, V; Piccart, MJ; Rezai, M; Steger, G; Turri, S; Untch, M; Urban, P; Von Minckwitz, G; Zardavas, D1
Autret, A; Bertucci, F; Boher, JM; Camerlo, J; Campone, M; Charafe-Jauffret, E; Extra, JM; Gonçalves, A; Guerin, M; Hervieu, A; Isambert, N; Lokiec, F; Pakradouni, J; Provansal, M; Rezai, K; Sabatier, R; Viens, P1
Messina, C; Messina, M; Zanardi, E1
Barriga, S; Bourayou, N; Campone, M; Chen, SC; Di Leo, A; Forrester, T; Freedman, OC; Frenzel, M; Garnica Jaliffe, G; Goetz, MP; Huober, J; Manso, L; Paluch-Shimon, S; Park, IH; Smith, IC; Sohn, J; Toi, M; Trédan, O1
Pondé, N; Tryfonidis, K; Zardavas, D1
Alba, E; Bachelot, T; Burris, HA; Campone, M; Erdkamp, F; Favret, AM; Germa, C; Hart, LL; Hegg, R; Jakobsen, E; Janni, W; Miller, M; Sonke, GS; Souami, F; Sutradhar, S; Verma, S; Villanueva, C; Wheatley-Price, P; Wist, E1
Kim, ES1
Iacobucci, G1
Anders, CK; Carey, LA; Dees, EC; Hu, Z; Kornblum, ZA; Marcom, PK; McRee, AJ; Moore, DT; Perou, CM; Phipps, R; Reeder-Hayes, K; Weck, KE; Zamboni, WC1
Arteaga, CL; Beck, JT; Cameron, DA; Conte, P; Germa, C; Hart, LL; Hortobagyi, GN; Jakobsen, E; Lindquist, D; Mondal, S; O'Shaughnessy, J; Petrakova, K; Sonke, GS; Souami, F; Villanueva, C1
Augereau, P; Berton Rigaud, D; Bourbouloux, E; Campone, M; Frenel, JS; Gourmelon, C; Patsouris, A; Robert, M2
Bachelot, T; Chan, S; Farci, D; Han, HS; Jerusalem, G; Kong, A; Massacesi, C; Mouhaër, SL; Pistilli, B; Pluard, T; Robinson, D; Saura, C; Tomaso, ED; Urban, P; Urruticoechea, A1
Aghaei, M; Jafari, SM; Joshaghani, HR; Panjehpour, M1
Bachelot, T; Blau, S; Bordonaro, R; Ciruelos, E; Csőszi, T; Decker, T; Dharan, B; Di Leo, A; Egle, D; El-Hashimy, M; Janni, W; Johnston, S; Kalev, D; Lee, KS; Lønning, PE; Mouret-Reynier, MA; O'Regan, R; Schirone, A; Sellami, D; Tjan-Heijnen, VCG; Weber, D1
Andre, F; Bailleux, C; Bardia, A; Condorelli, R; Dubois, J; Iafrate, AJ; Lacroix, L; Lanman, RB; Nagy, RJ; O'Shaughnessy, J; Scott, V; Spring, L1
Belli, C; Criscitiello, C; Curigliano, G; D'Amico, P; Duso, BA; Locatelli, M; Mazzarella, L; Minchella, I; Trapani, D; Viale, G1
Iwata, H1
Alba, E; Auñón, PZ; Bachelot, T; Beck, TJ; Campone, M; Diab, S; Esteva, FJ; Gil-Gil, M; Janni, W; Kral, Z; Lopez, R; Miller, M; Pluard, TJ; Richards, P; Ryvo, L; Sutradhar, S; Tsai, M; Ward, P1
Alebachew, E; Beaver, JA; Bi, Y; Bloomquist, E; Blumenthal, GM; Chang, CJG; Fu, W; Goldberg, KB; Ibrahim, A; Liu, Q; Palmby, TR; Patel, P; Pazdur, R; Pierce, WF; Shah, A; Sridhara, R; Tang, S; Tilley, A; Yu, J; Zhao, P1
Burris, HA1
Hernández-Steller, H; Landaverde, DU; Ramos-Esquivel, A; Savard, MF1
Corona, SP; Generali, D1
Kotake, T; Toi, M1
Assi, T; Bakouny, Z; El Rassy, E; Kattan, J1
Alba, E; Burris, HA; Campone, M; Chandiwana, D; Dalal, AA; Janni, W; Monaco, M; O'Shaughnessy, J; Sutradhar, S; Verma, S1
Bardia, A; Spring, L1
Arteaga, CL; Blackwell, KL; Burris, HA; Cameron, DA; Campone, M; Conte, P; Elmeliegy, M; Germa, C; Hortobagyi, GN; Janni, W; Miller, M; Mondal, S; O'Shaughnessy, J; Paluch-Shimon, S; Petrakova, K; Sonke, GS; Stemmer, SM; Su, F; Verma, S; Winer, EP; Yap, YS1
Dhar, V; Parylo, S; Patibandla, P; Sokoloff, A; Vennepureddy, A1
Gonçalves, A1
Abdel-Razeq, H1
Bhattacharyya, D; Bhattacharyya, S; Biskupiak, J; Brixner, D; Dalal, AA; May, JR; Mishra, D; Mistry, R; Oderda, G; Suri, G; Tang, D; Young, K1
Babu, KG; Bardia, A; Campos-Gomez, S; Carlson, G; Chow, L; Colleoni, M; De Laurentiis, M; Diaz-Padilla, I; El-Saghir, N; Franke, F; Germa, C; Harbeck, N; Hirawat, S; Hughes, G; Hurvitz, SA; Im, SA; Im, YH; Jung, KH; Kuemmel, S; Lee, KS; Liu, MC; Lu, YS; Sohn, J; Tripathy, D; Villanueva Vazquez, R; Wheatley-Price, P1
Foukakis, T1
Beck, JT; Bianchi, GV; Chia, S; De la Cruz-Merino, L; De Laurentiis, M; Esteva, FJ; Fasching, PA; Im, SA; Jerusalem, G; Martín, M; Miller, M; Neven, P; Nusch, A; Petrakova, K; Pivot, X; Rodriguez Lorenc, K; Slamon, DJ; Sonke, GS; Taran, T; Vidam, G; Wang, Y1
Romero, D1
Lynce, F; Shajahan-Haq, AN; Swain, SM1
Abraham, J; Lee, SS; Scott, SC1
Fojo, T; Laderian, B1
Bjelic-Radisic, V; Kapp, KS; Partl, R; Pötscher, M; Regitnig, P; Tauber, G1
Bhattacharyya, D; Bhattacharyya, S; Biskupiak, J; Brixner, D; Dalal, AA; Hettle, R; May, JR; Mishra, D; Mistry, R; Oderda, G; Suri, G; Tang, D; Young, K1
Hecht, KA; Selby, C1
Lau, G; Palumbo, A; Saraceni, M1
Desideri, I; Livi, L; Meattini, I; Scotti, V; Simontacchi, G1
Augereau, P; Bourbouloux, E; Campone, M; Frenel, JS; Gourmelon, C; Patsouris, A; Rigaud, DB; Robert, M1
Al, MJ; Armstrong, N; Büyükkaramikli, NC; de Groot, S; Duffy, S; Fayter, D; Kleijnen, J; Portegijs, P; Riemsma, R1
Arteaga, CL; Awada, A; Baselga, J; Bourdeau, L; Campone, M; Chia, S; Clemons, M; Cortés, J; De Laurentiis, M; El-Hashimy, M; Hurvitz, S; Im, SA; Ito, Y; Iwata, H; Jagiełło-Gruszfeld, A; Jiang, Z; Jonat, W; Le Mouhaër, S; Masuda, N; Pistilli, B; Sankaran, B; Sellami, D; Tseng, LM1
Aplin, AE; Teh, JLF1
Afghahi, A; Diamond, JR; Shagisultanova, E; Weiss, J1
Ma, J; Peng, L; Tan, C; Wan, X; Zeng, X; Zhang, Y1
Balkenhol, M; Beißbarth, T; Blazquez, R; Bleckmann, A; Evert, M; Hanisch, UK; Korf, U; Perera-Bel, J; Proescholdt, M; Pukrop, T; Reinz, E; Riemenschneider, MJ; Ritter, U; Salinas, G; Schatlo, B; Schildhaus, HU; Schulz, M; Seitz, S; Siam, L; Stadelmann, C; Utpatel, K; Vollmer, E; Wachter, A; Wiemann, S; Wlochowitz, D; Wolff, A1
Cardoso, F; Ribnikar, D; Volovat, SR1
Choo, JR; Lee, SC1
Bøttcher, TM; Cold, S; Jensen, AB1
Bacon, J; Bonventre, JV; Chappell, JC; Chiang, AY; Hall, SD; Kulanthaivel, P; Pak, YA; Royalty, J; Turner, PK1
Finn, RS; Friedlander, M; Lee, CK; Lee, KWC; Lim, E; Loi, S; Lord, S; Lynch, J; Martin, A1
Niraula, S1
De Angelis, C; Ekinci, E; Flajc, G; Liu, X; Rascon, K; Trivedi, MV1
Chen, IC; Lu, YS; Yang, MH1
Huang, HW; Huang, LS; Li, XY; Lin, JZ; Wang, HB; Xu, QN1
Amoroso, V; Barni, S; Berruti, A; Borgonovo, K; Cabiddu, M; Ghidini, A; Ghilardi, M; Parati, MC; Pedersini, R; Petrelli, F1
Allen, RJ; Bishop, RT; de Ridder, D; Idris, AI; Lefley, DV; Marino, S; Ottewell, PD; Sims, AH; Wang, N1
Long, EF; Zhang, B1
Degenhardt, T; Eggersmann, TK; Gluz, O; Harbeck, N; Wuerstlein, R1
DuRoss, AN; Eaton, CT; Landry, MR; Neufeld, MJ; Rosch, JG; Sahay, G; Sun, C; Thomas, CR1
Arteaga, CL; Balko, JM; Bardia, A; Bauer, JA; Behdad, A; Cristofanilli, M; Croessmann, S; Cruz, MR; Dugger, TC; Ericsson, PG; Formisano, L; Guerrero-Zotano, AL; Guo, Y; Hanker, AB; He, W; Jansen, VM; Lanman, RB; Lee, KM; Lu, Y; Mayer, IA; Miller, M; Nagy, RJ; Nixon, MJ; O'Shaughnessy, J; Sanders, ME; Schwarz, LJ; Servetto, A; Shyr, Y; Solovieff, N; Su, F; Sudhan, DR1
Chen, Q; Dai, Y; Guo, Q; Lin, X; Xu, R; Ye, L; Zhang, Y1
Cai, Z; Enatsu, S; Ishiguro, H; Omori, Y1
Cheng, Y; Cristofanilli, M; Cui, S; Feng, J; Gao, J; Geng, C; Gu, K; Hu, X; Jiang, Z; Li, W; Liu, T; Lu, X; Ning, Z; Ouyang, Q; Ouyang, T; Pan, Y; Sun, T; Sun, Y; Tong, Z; Wang, H; Wang, S; Wang, X; Yin, Y; Zhang, Q1
D'Angelillo, RM; Dell'Aquila, E; Fiore, M; Greco, C; Ippolito, E; Petrianni, GM; Ramella, S; Silipigni, S; Tonini, G1
Bardia, A; Campos-Gomez, S; Chakravartty, A; Chow, L; Colleoni, M; Franke, F; Gounaris, I; Harbeck, N; Hughes, G; Hurvitz, S; Im, SA; Jung, KH; Lee, KS; Lu, YS; Rodriguez-Lorenc, K; Sohn, J; Taran, T; Tripathy, D; Villanueva-Vazquez, R1
Andrews, C; Bardia, A; Barry, WT; Goel, S; Mayer, EL; Pernas, S; Rees, R; Spring, LM; Tahara, RK; Tan-Wasielewski, Z; Tolaney, SM; Trippa, L; Winer, EP1
Harada, M; Iida, Y; Inao, T; Kartika, ID; Kotani, H; Okimoto, T; Shiba, E; Tanino, R1
Yardley, DA1
Al-Showbaki, LN; Alqaisi, HA; Awidi, AS; Awidi, MA; Bawa'neh, HS; El Khatib, OH; Khalil, LT; Mansour, AT1
Rugo, HS1
Biskupiak, J; Brixner, D; Dalal, AA; Oderda, G; Tang, D; Zacker, C1
Cersosimo, RJ1
Hu, X; Sharma, S; Wang, MH; Yao, HP; Zeng, JY; Zhang, R; Zhou, YQ; Zhuang, CM1
Antón, P; Arribas, J; Baselga, J; Eichhorn, PJ; García-García, C; Hahn, WC; Ibrahim, YH; Kim, SY; Marlow, S; Parra, JL; Pérez-Garcia, J; Prat, A; Prudkin, L; Rodríguez, O; Sánchez, G; Scaltriti, M; Serra, V1
Chen, X; Hao, M; Liu, J; Mao, Y; Shen, K; Shen, Y; Sun, X; Wang, J; Zhao, M; Zu, L1
Wang, Q; Weisberg, E; Zhao, JJ1
Sharma, S; Wang, MH; Yao, HP; Zhang, R; Zhou, J; Zhou, YQ1
Arteaga, CL; Chanthaphaychith, S; Dahlman, K; Rexer, BN1
Abramson, VG; Arteaga, CL; Balko, JM; Cantley, LC; Forero, A; Isakoff, SJ; Kuba, MG; Li, Y; Mayer, IA; Sanders, ME; Van den Abbeele, AD; Winer, E; Yap, JT1
Das, S; De Chatterjee, A; Guevara, P; Metta-Magaña, AJ; Nuñez, JE; Ramirez, V; Varela, JG; Varela-Ramirez, A; Villagrán, D1
Dedes, KJ; Fink, D; Gutsche, K; Imesch, P; Samartzis, EP; Stucki, M1
Brower, V1
Abramson, V; Arteaga, CL; Balko, JM; Estrada, MV; Fox, EM; Garrett, JT; González-Angulo, AM; Kelley, MC; Kuba, MG; Mayer, IA; Meszoely, IM; Mills, GB; Red-Brewer, M; Rizzo, M; Schwarz, LJ1
Aversa, C; Geuna, E; Martinello, R; Milani, A; Montemurro, F; Scaltriti, M; Valabrega, G1
Mayer, EL2
Choi, HJ; Choi, JW; Jang, KS; Kang, JH; Kim, HY; Kim, S; Kong, G; Lee, JY; Oh, SH; Oh, YH; Park, JH; Shin, DH; Son, T; Won, HY; Woo, JK; Yi, K1
Dickler, MN; Murphy, CG1
Dawood, S; Rastogi, S; Sirohi, B1
Lorimer, E; Tyburski, MD; Williams, CL; Wilson, JM1
Rugo, HS; Vidula, N1
Estévez, LG; García, E; Hidalgo, M1
Kimura-Tsuchiya, R; Saji, S; Sasaki, E1
Ademuyiwa, F; Ellis, MJ; Griffith, M; Griffith, OL; Guo, Z; Han, J; Hoog, J; Lockhart, C; Luo, J; Ma, CX; Mardis, E; Nagaraj, G; Naughton, M; Pluard, T; Ramu, A; Skidmore, ZL; Spies, NC; Suresh, R; Thomas, S; Trani, L1
Konecny, GE1
Guo, R; Hu, Y; Ji, W; Liu, J; Wei, J; Zhang, J; Zhi, X; Zhou, Y1
Benada, J; Burdova, K; Jenikova, G; Kleiblova, P; Macurek, L; Pechackova, S1
Braun, GB; Chung, TD; Kotamraju, VR; Paasonen, L; Pellecchia, M; Ruoslahti, E; Sharma, S; She, ZG; Sugahara, KN; Teesalu, T; Wu, B; Yliperttula, M1
Finn, RS; O'Leary, B; Turner, NC1
Beckmann, RP; Beeram, M; Chan, EM; Cronier, DM; Flaherty, KT; Frenzel, M; Fulford, AD; Gandhi, L; Goldman, JW; Hilton, JF; Kulanthaivel, P; Li, LQ; Martinez, R; Nasir, A; Nguyen, TS; Papadopoulos, KP; Patnaik, A; Rasco, DW; Rosen, LS; Schade, AE; Shapiro, GI; Tolaney, SM; Tolcher, AW; Wen, PY1
Alexander, BM; Claus, EB; Du, R; Goel, S; Guo, H; Hayashi, M; Iglehart, JD; Kang, YJ; Krop, IE; Ligon, AH; Ligon, KL; Lin, NU; Luu, V; Marco, E; Nguyen, QD; Ni, J; Ramkissoon, LA; Ramkissoon, SH; Roberts, TM; Stover, DG; Wang, ZC; Winer, EP; Xie, S; Yuan, GC; Zhao, JJ1
O'Sullivan, CC1
Bardia, A; Beck, JT; Conte, P; Curigliano, G; Dhuria, S; Di Tomaso, E; Gómez Pardo, P; Hurvitz, SA; Lolkema, MP; Martínez García, M; Meric-Bernstam, F; Miller, M; Penault-Llorca, F; Solovieff, N; Tang, Z1
Lim, JS; Turner, NC; Yap, TA1
Liu, P; Xu, B; Zhang, C1
Alba, E; André, F; Arteaga, CL; Bachelot, T; Blackwell, KL; Blau, S; Burdaeva, O; Burris, HA; Cameron, DA; Campone, M; Chan, A; Conte, P; Favret, AM; Germa, C; Grischke, EM; Hart, LL; Hirawat, S; Hortobagyi, GN; Jakobsen, E; Janni, W; Marschner, N; Miller, M; Nusch, A; O'Shaughnessy, J; Paluch-Shimon, S; Petrakova, K; Sonke, GS; Souami, F; Stemmer, SM; Tseng, LM; Verma, S; Villanueva, C; Winer, EP; Wist, E; Xuan, F; Yap, YS; Yardley, D1
Burki, TK1
Baselga, J; Bhatt, T; Chandarlapaty, S; Dickler, M; Giri, D; Li, Z; Rosen, N; Scaltriti, M; Yang, C1
Batista López, N; Beck, JT; Campone, M; Chan, A; Delaloge, S; Di Tomaso, E; Dirix, L; Goteti, S; Hegg, R; Khan, QJ; Krivorotko, P; Manikhas, A; Martín, M; Massacesi, C; O'Shaughnessy, J; Ramos Vázquez, M; Ruiz Borrego, M; Shtivelband, M; Urban, P1
Aghajanian, C; Barry, WT; Bell-McGuinn, KM; Berger, MF; Birrer, M; Cantley, LC; Farooq, S; Hok, RC; Liu, H; Liu, J; Luo, W; Matulonis, UA; Mills, GB; Obermayer, E; Palakurthi, S; Solit, DB; Spagnoletti, T; Taylor, BS; Westin, SN; Whalen, C; Winer, E; Won, H; Wulf, GM1
Ju, W; Kim, CY; Kim, HJ; Kim, SC; Kim, YH; Lee, SY1
Basse, C; Dieras, V; Jobard, A; Le Tourneau, C; Loirat, D; Ricci, F; Romano, E; Sablin, MP1
Arteaga, CL; Bauer, JA; Bhola, NE; Dugger, TC; Ericsson, PG; Estrada, MV; Formisano, L; Hutchinson, KE; Jansen, VM; Knudsen, ES; Lee, KM; Moore, PD; Pishvaian, MJ; Pohlmann, PR; Riddle, DA; Sánchez, V; Sanders, ME; Wei, W; Witkiewicz, AK1
Kwok, C; Luo, H; McMahon, G; Nam, JO; Patel, N; Phillips, A; Schlaepfer, DD; Stupack, DG; Tanjoni, I; Tomar, A; Uryu, S; Walsh, C1
Conti, AA; Dilaghi, B; Modesti, PA; Nozzoli, C1
Crowder, RJ; Ellis, MJ; Gao, F; Guintoli, T; Lin, L; Ma, CX; Phommaly, C; Sanchez, CG1
Hong, S; Kim, J1
Appert, HE; Bartsch, JE; Staren, ED1

Reviews

87 review(s) available for alpha-aminopyridine and Breast Cancer

ArticleYear
Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 01-20, Volume: 40, Issue:3

    Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Chemotherapy, Adjuvant; Consensus; Disease-Free Survival; Female; Humans; Medical Oncology; Neoplasm Staging; Protein Kinase Inhibitors; Time Factors

2022
[Development of CDK4 & 6 Inhibitor Abemaciclib in Breast Cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2021, Volume: 48, Issue:12

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Humans; Protein Kinase Inhibitors; Receptor, ErbB-2

2021
Systematic Review of Molecular Biomarkers Predictive of Resistance to CDK4/6 Inhibition in Metastatic Breast Cancer.
    JCO precision oncology, 2022, Volume: 6

    Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Biomarkers, Tumor; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Female; Humans; Piperazines; Prognosis; Purines; Pyridines

2022
Cyclin-dependent Kinases 4/6 Inhibitors in Neuroendocrine Neoplasms: from Bench to Bedside.
    Current oncology reports, 2022, Volume: 24, Issue:6

    Topics: Aminopyridines; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Lung Neoplasms; Neuroendocrine Tumors; Protein Kinase Inhibitors; Small Cell Lung Carcinoma

2022
Ribociclib efficacy in special populations and analysis of patient-reported outcomes in the MONALEESA trials.
    Expert review of anticancer therapy, 2022, Volume: 22, Issue:4

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cyclin-Dependent Kinase 4; Female; Humans; Patient Reported Outcome Measures; Purines; Quality of Life; Randomized Controlled Trials as Topic; Receptor, ErbB-2

2022
Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity.
    International journal of molecular sciences, 2022, Jun-11, Volume: 23, Issue:12

    Topics: Aminopyridines; Breast Neoplasms; Cell Cycle; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Protein Kinase Inhibitors; Quality of Life

2022
Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib.
    The oncologist, 2022, 10-01, Volume: 27, Issue:10

    Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estrogens; Female; Humans; Mitogens; Protein Kinase Inhibitors; Tumor Suppressor Proteins

2022
Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review.
    ESMO open, 2022, Volume: 7, Issue:6

    Topics: Aminopyridines; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Protein Kinase Inhibitors; Quality of Life

2022
Cyclin-dependent kinase 4/6 inhibitor-associated thromboembolism: a critical evaluation of the current evidence.
    Journal of thrombosis and haemostasis : JTH, 2023, Volume: 21, Issue:4

    Topics: Aminopyridines; Anticoagulants; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Humans; Protein Kinase Inhibitors; Pyridines; Venous Thromboembolism

2023
Abemaciclib: A Review in Early Breast Cancer with a High Risk of Recurrence.
    Targeted oncology, 2023, Volume: 18, Issue:2

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Receptor, ErbB-2

2023
Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    PharmacoEconomics, 2023, Volume: 41, Issue:7

    Topics: Adjuvants, Immunologic; Adult; Aminopyridines; Benzimidazoles; Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; State Medicine; Technology Assessment, Biomedical

2023
Advances in pharmacotherapies that target the cell cycle for treatment of breast cancer: where are we at today?
    Expert opinion on pharmacotherapy, 2023, Volume: 24, Issue:8

    Topics: Aminopyridines; Breast Neoplasms; Cell Cycle; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Molecular Targeted Therapy; Protein Kinase Inhibitors; Pyridines

2023
Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry.
    Breast cancer research and treatment, 2023, Volume: 201, Issue:2

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Receptor, ErbB-2

2023
HR+/HER2- Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review.
    Current oncology (Toronto, Ont.), 2023, 06-02, Volume: 30, Issue:6

    Topics: Aged; Aminopyridines; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local

2023
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors: existing and emerging differences.
    JNCI cancer spectrum, 2023, 07-03, Volume: 7, Issue:4

    Topics: Aminopyridines; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Humans

2023
Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor-Positive, ERBB2-Negative Breast Cancer: A Review.
    JAMA oncology, 2023, 09-01, Volume: 9, Issue:9

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Protein Kinase Inhibitors; Receptor, ErbB-2; Triple Negative Breast Neoplasms

2023
Mechanism of CDK4/6 Inhibitor Resistance in Hormone Receptor-positive Breast Cancer and Alternative Treatment Strategies.
    Anticancer research, 2023, Volume: 43, Issue:12

    Topics: Aminopyridines; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinase Inhibitor Proteins; Female; Humans; Protein Kinase Inhibitors

2023
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019).
    Bioorganic & medicinal chemistry letters, 2019, 10-15, Volume: 29, Issue:20

    Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cell Cycle Checkpoints; Cyclin-Dependent Kinases; Drug Discovery; Humans; Indoles; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Pyrimidines; Transcription Factors

2019
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
    The Lancet. Oncology, 2019, Volume: 20, Issue:10

    Topics: Aminopyridines; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Everolimus; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Paclitaxel; Piperazines; Postmenopause; Progression-Free Survival; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone

2019
Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer.
    Japanese journal of clinical oncology, 2019, Dec-18, Volume: 49, Issue:11

    Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Japan; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines

2019
The efficacy and safety of neoadjuvant buparlisib for breast cancer: A meta-analysis of randomized controlled studies.
    Medicine, 2019, Volume: 98, Issue:44

    Topics: Aminopyridines; Breast Neoplasms; Humans; Morpholines; Neoadjuvant Therapy; Phosphoinositide-3 Kinase Inhibitors; Randomized Controlled Trials as Topic; Receptor, ErbB-2

2019
[2019 international oncology news: A compendium].
    Bulletin du cancer, 2020, Volume: 107, Issue:2

    Topics: Aminopyridines; Breast Neoplasms; Clinical Trials as Topic; Digestive System Neoplasms; Female; Genital Neoplasms, Female; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Neoplasms; Neoplasms, Unknown Primary; Prostatic Neoplasms; Purines

2020
The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC).
    Acta oncologica (Stockholm, Sweden), 2020, Volume: 59, Issue:6

    Topics: Alopecia; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estrogen Receptor alpha; Female; Fulvestrant; Germany; Humans; Incidence; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Progesterone; Survival Rate; Tamoxifen

2020
Increased risk of cardiac conduction abnormalities with ribociclib in patients with metastatic breast cancer: A combined analysis of phase III randomized controlled trials.
    Hematology/oncology and stem cell therapy, 2021, Volume: 14, Issue:3

    Topics: Aminopyridines; Breast Neoplasms; Cardiac Conduction System Disease; Clinical Trials, Phase III as Topic; Female; Humans; Neoplasm Metastasis; Purines; Randomized Controlled Trials as Topic; Risk Factors

2021
Abemaciclib: safety and effectiveness of a unique cyclin-dependent kinase inhibitor.
    Expert opinion on drug safety, 2020, Volume: 19, Issue:8

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Cell Cycle Checkpoints; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Protein Kinase Inhibitors; Quality of Life

2020
Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer.
    Future oncology (London, England), 2020, Volume: 16, Issue:33

    Topics: Aminopyridines; Benzimidazoles; Biomarkers, Tumor; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Molecular Targeted Therapy; Prognosis; Protein Kinase Inhibitors; Treatment Outcome

2020
    Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2022, Volume: 30, Issue:2

    Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea

2022
Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
    Cancer treatment reviews, 2020, Volume: 90

    Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Neoplasm Metastasis; Network Meta-Analysis; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic

2020
Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib.
    Clinical pharmacokinetics, 2020, Volume: 59, Issue:12

    Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines

2020
Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.
    Expert review of anticancer therapy, 2021, Volume: 21, Issue:1

    Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quality of Life

2021
Ribociclib plus fulvestrant in the treatment of breast cancer.
    Expert review of anticancer therapy, 2021, Volume: 21, Issue:1

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Female; Fulvestrant; Humans; Progression-Free Survival; Purines; Randomized Controlled Trials as Topic; Survival Rate

2021
Risk-adapted adjuvant therapy of luminal early breast cancer in 2020.
    Current opinion in obstetrics & gynecology, 2021, 02-01, Volume: 33, Issue:1

    Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Benzimidazoles; Breast Neoplasms; COVID-19; Female; Gene Expression Profiling; Humans; Ki-67 Antigen; Neoadjuvant Therapy; Piperazines; Protein Kinase Inhibitors; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Risk Assessment; SARS-CoV-2

2021
Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis.
    BioMed research international, 2020, Volume: 2020

    Topics: Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Clinical Trials as Topic; Female; Humans; Morpholines; Mutation; Network Meta-Analysis; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Progression-Free Survival; Signal Transduction; Thiazoles; Treatment Outcome

2020
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.
    European journal of clinical investigation, 2021, Volume: 51, Issue:7

    Topics: Aminopyridines; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Letrozole; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Trastuzumab

2021
[Targeting the cyclin-dependent kinases 4/6 in advanced breast cancers].
    Bulletin du cancer, 2021, Volume: 108, Issue:9

    Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cell Cycle; Clinical Trials, Phase III as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Piperazines; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic; Retinoblastoma Binding Proteins; Ubiquitin-Protein Ligases

2021
CDK4/6 inhibitor-induced colitis: a case report and review of the literature.
    BMJ case reports, 2021, Jul-26, Volume: 14, Issue:7

    Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colitis; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Letrozole; Purines; Receptor, ErbB-2; Receptors, Estrogen

2021
HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles.
    Current cancer drug targets, 2017, Volume: 17, Issue:7

    Topics: Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Liver; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Transcription Factors

2017
Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer.
    Expert opinion on drug metabolism & toxicology, 2017, Volume: 13, Issue:5

    Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Metastasis; Purines; Receptor, ErbB-2

2017
Recent advances of highly selective CDK4/6 inhibitors in breast cancer.
    Journal of hematology & oncology, 2017, 04-24, Volume: 10, Issue:1

    Topics: Aminopyridines; Antineoplastic Agents, Immunological; Benzimidazoles; Breast Neoplasms; Cell Cycle; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Screening Assays, Antitumor; Female; Humans; Molecular Targeted Therapy; Neoplasm Proteins; Piperazines; Purines; Pyridines; Therapies, Investigational

2017
Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors: Palbociclib and ribociclib.
    Breast (Edinburgh, Scotland), 2017, Volume: 35

    Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Molecular Targeted Therapy; Neutropenia; Piperazines; Purines; Pyridines

2017
A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
    Current medical research and opinion, 2017, Volume: 33, Issue:9

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic; Triazoles

2017
Treatment for the endocrine resistant breast cancer: Current options and future perspectives.
    The Journal of steroid biochemistry and molecular biology, 2017, Volume: 172

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Everolimus; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Morpholines; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction

2017
Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
    The oncologist, 2017, Volume: 22, Issue:9

    Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cell Cycle; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Interactions; Female; Humans; Molecular Targeted Therapy; Neutropenia; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines

2017
Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Breast cancer research and treatment, 2017, Volume: 166, Issue:1

    Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic; Treatment Outcome

2017
Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
    Future oncology (London, England), 2017, Volume: 13, Issue:24

    Topics: Aminopyridines; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Evaluation, Preclinical; Female; Humans; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone

2017
Extending indication of cyclin-dependent kinase 4/6 inhibitors in the adjuvant and neoadjuvant setting.
    Current opinion in oncology, 2017, Volume: 29, Issue:6

    Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Neoadjuvant Therapy; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic

2017
Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
    Expert review of clinical pharmacology, 2017, Volume: 10, Issue:11

    Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Neoplasm Metastasis; Neutropenia; Postmenopause; Purines; Receptor, ErbB-2

2017
Risks and benefits from CDK inhibitors for advanced HR+ Her 2- breast cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 12-01, Volume: 28, Issue:12

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinases; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Risk Assessment; Triazoles

2017
CDK4/6 blockade in breast cancer: current experience and future perspectives.
    Expert opinion on investigational drugs, 2017, Volume: 26, Issue:12

    Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Design; Female; Humans; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines

2017
Abemaciclib: First Global Approval.
    Drugs, 2017, Volume: 77, Issue:18

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Breast Neoplasms; Cyclin-Dependent Kinases; Drug Approval; Estradiol; Female; Fulvestrant; Humans; Neoplasm Metastasis; United States; United States Food and Drug Administration

2017
Clinical development of CDK4/6 inhibitor for breast cancer.
    Breast cancer (Tokyo, Japan), 2018, Volume: 25, Issue:4

    Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptors, Estrogen

2018
Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
    Expert review of anticancer therapy, 2018, Volume: 18, Issue:3

    Topics: Aminopyridines; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Design; Female; Humans; Neoplasm Metastasis; Progression-Free Survival; Purines

2018
Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials.
    Breast cancer (Tokyo, Japan), 2018, Volume: 25, Issue:4

    Topics: Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Piperazines; Postmenopause; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic; Treatment Outcome

2018
Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer.
    Drug design, development and therapy, 2018, Volume: 12

    Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Hormone Antagonists; Humans; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Signal Transduction; Treatment Outcome

2018
Abemaciclib for the treatment of breast cancer.
    Expert opinion on pharmacotherapy, 2018, Volume: 19, Issue:5

    Topics: Aminopyridines; Benzimidazoles; Biomarkers; Brain Neoplasms; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Therapy, Combination; Estradiol; Female; Fulvestrant; Humans; Neoplasm Staging; Prognosis

2018
Different inhibitors for the same target in metastatic luminal breast cancer: is there any difference?
    Future oncology (London, England), 2018, Volume: 14, Issue:9

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cell Cycle; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Piperazines; Purines; Pyridines

2018
Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
    Breast cancer (Tokyo, Japan), 2018, Volume: 25, Issue:5

    Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen

2018
Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2019, Volume: 25, Issue:1

    Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Forecasting; Humans; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Treatment Outcome

2019
Current frontline endocrine treatment options for women with hormone receptor-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative advanced-stage breast cancer.
    Hematology/oncology and stem cell therapy, 2019, Volume: 12, Issue:1

    Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Neoplasm Staging; Piperazines; Purines; Pyridines; Receptor, ErbB-2

2019
CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities.
    Pharmacology & therapeutics, 2018, Volume: 191

    Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines

2018
Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.
    Seminars in oncology, 2017, Volume: 44, Issue:6

    Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Synergism; Humans; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen

2017
CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Seminars in oncology, 2017, Volume: 44, Issue:6

    Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Humans; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines

2017
Review of Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer.
    The Annals of pharmacotherapy, 2019, Volume: 53, Issue:2

    Topics: Aminopyridines; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease Progression; Female; Humans; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2

2019
Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer.
    The Annals of pharmacotherapy, 2019, Volume: 53, Issue:2

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Chemotherapy-Induced Febrile Neutropenia; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Molecular Targeted Therapy; Protein Kinase Inhibitors; Receptor, ErbB-2

2019
An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer.
    Drugs, 2018, Volume: 78, Issue:13

    Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Female; Humans; Molecular Targeted Therapy; Piperazines; Progression-Free Survival; Protein Kinase Inhibitors; Purines; Pyridines

2018
Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    PharmacoEconomics, 2019, Volume: 37, Issue:2

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Models, Economic; Purines; Randomized Controlled Trials as Topic; Receptors, Estrogen; Technology Assessment, Biomedical

2019
Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 02-01, Volume: 25, Issue:3

    Topics: Aminopyridines; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Lymphocytes, Tumor-Infiltrating; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptors, Estrogen; Tumor Microenvironment

2019
Targeting CDK4/6 pathways and beyond in breast cancer.
    Breast (Edinburgh, Scotland), 2019, Volume: 43

    Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Humans; Molecular Targeted Therapy; Piperazines; Progression-Free Survival; Protein Kinase Inhibitors; Purines; Pyridines; Receptors, Estrogen; Receptors, Progesterone; Signal Transduction

2019
CDK4-6 inhibitors in breast cancer: current status and future development.
    Expert opinion on drug metabolism & toxicology, 2018, Volume: 14, Issue:11

    Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzimidazoles; Biomarkers, Tumor; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Piperazines; Progression-Free Survival; Protein Kinase Inhibitors; Purines; Pyridines

2018
Treatment of advanced HR+/HER2- breast cancer with new targeted agents in combination with endocrine therapy: a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib.
    Acta oncologica (Stockholm, Sweden), 2019, Volume: 58, Issue:2

    Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Disease Progression; Drugs, Investigational; Everolimus; Female; Humans; Molecular Targeted Therapy; Piperazines; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Cytoplasmic and Nuclear; Treatment Outcome

2019
The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis.
    Breast cancer research and treatment, 2019, Volume: 174, Issue:1

    Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Asian People; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Piperazines; Progression-Free Survival; Protein Kinase Inhibitors; Purines; Pyridines

2019
Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.
    The Annals of pharmacotherapy, 2019, Volume: 53, Issue:5

    Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Female; Humans; Neoplasm Metastasis; Premenopause; Purines; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen

2019
Pharmacokinetic drug evaluation of abemaciclib for advanced breast cancer.
    Expert opinion on drug metabolism & toxicology, 2019, Volume: 15, Issue:2

    Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease-Free Survival; Female; Humans; Neoplasm Metastasis; Protein Kinase Inhibitors

2019
CDK4/6 inhibition versus mTOR blockade as second-line strategy in postmenopausal patients with hormone receptor-positive advanced breast cancer: A network meta-analysis.
    Medicine, 2019, Volume: 98, Issue:1

    Topics: Aminopyridines; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; ErbB Receptors; Everolimus; Female; Fulvestrant; Humans; Network Meta-Analysis; Piperazines; Postmenopause; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; TOR Serine-Threonine Kinases

2019
Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials.
    Breast cancer research and treatment, 2019, Volume: 174, Issue:3

    Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Piperazines; Prospective Studies; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptors, Estrogen; Survival Analysis; Treatment Outcome

2019
CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2019, Volume: 33, Issue:2

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic

2019
Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis.
    Targeted oncology, 2019, Volume: 14, Issue:2

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Piperazines; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone

2019
Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2019, 08-01, Volume: 76, Issue:16

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Dose-Response Relationship, Drug; Fatigue; Female; Gastrointestinal Diseases; Humans; Molecular Targeted Therapy; Neoplasm Staging; Neutropenia; Piperazines; Progression-Free Survival; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic

2019
Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer.
    Expert opinion on investigational drugs, 2015, Volume: 24, Issue:3

    Topics: Aminopyridines; Animals; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Molecular Targeted Therapy; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Signal Transduction

2015
Targeting breast cancer with CDK inhibitors.
    Current oncology reports, 2015, Volume: 17, Issue:5

    Topics: Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cell Cycle; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines

2015
The Role of CDK4/6 Inhibition in Breast Cancer.
    The oncologist, 2015, Volume: 20, Issue:5

    Topics: Aminopyridines; Breast Neoplasms; Cell Cycle; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; DNA Breaks, Double-Stranded; Estrogen Receptor alpha; Female; Flavonoids; Humans; Piperazines; Piperidines; Protein Kinase Inhibitors; Purines; Pyridines

2015
Buparlisib in breast cancer.
    Future oncology (London, England), 2015, Volume: 11, Issue:10

    Topics: Aminopyridines; Animals; Antineoplastic Agents; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Evaluation, Preclinical; Female; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases; Treatment Outcome

2015
Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data.
    Clinical breast cancer, 2016, Volume: 16, Issue:1

    Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines

2016
Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2016, Volume: 18, Issue:6

    Topics: Aminopyridines; Animals; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Mice; Molecular Targeted Therapy; Morpholines; Phosphatidylinositol 3-Kinases; Signal Transduction

2016
Cyclin-dependent kinase pathways as targets for women's cancer treatment.
    Current opinion in obstetrics & gynecology, 2016, Volume: 28, Issue:1

    Topics: Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Liposarcoma; Lymphoma, Mantle-Cell; Melanoma; Neoplasms, Germ Cell and Embryonal; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Signal Transduction

2016
Treating cancer with selective CDK4/6 inhibitors.
    Nature reviews. Clinical oncology, 2016, Volume: 13, Issue:7

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cell Cycle; Clinical Trials as Topic; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Forecasting; Humans; Molecular Targeted Therapy; Neoplasms; Piperazines; Purines; Pyridines

2016
CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update.
    Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:12

    Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2

2016

Trials

77 trial(s) available for alpha-aminopyridine and Breast Cancer

ArticleYear
Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib.
    JCO precision oncology, 2021, Volume: 5

    Topics: Adolescent; Adult; Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Circulating Tumor DNA; Double-Blind Method; Drug Resistance, Neoplasm; Female; Genomics; Humans; Middle Aged; Premenopause; Progression-Free Survival; Proportional Hazards Models; Purines; Receptor, ErbB-2; Transcription Factors; Young Adult

2021
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2021, Volume: 32, Issue:12

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Ki-67 Antigen; Neoplasm Recurrence, Local; Receptor, ErbB-2

2021
Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
    Breast cancer (Tokyo, Japan), 2022, Volume: 29, Issue:1

    Topics: Aged; Aminopyridines; Anastrozole; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Female; Humans; Japan; Letrozole; Middle Aged; Progression-Free Survival; Quality of Life; Receptors, Progesterone

2022
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, Mar-01, Volume: 28, Issue:5

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Perimenopause; Purines; Receptor, ErbB-2; Receptors, Estrogen

2022
Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2- Advanced Breast Cancer in the MONALEESA-3 Trial.
    Clinical breast cancer, 2022, Volume: 22, Issue:4

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Postmenopause; Purines

2022
Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 04-14, Volume: 28, Issue:8

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Circulating Tumor DNA; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Male; Mutation; Receptor, ErbB-2

2022
Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial.
    Breast (Edinburgh, Scotland), 2022, Volume: 62

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Hormones; Humans; Letrozole; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone

2022
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
    The New England journal of medicine, 2022, 03-10, Volume: 386, Issue:10

    Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Intention to Treat Analysis; Letrozole; Middle Aged; Neoplasm Grading; Neutropenia; Purines; Receptor, ErbB-2; Receptors, Estrogen; Survival Analysis

2022
Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial.
    Radiology and oncology, 2022, 05-17, Volume: 56, Issue:2

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Letrozole; Male; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone

2022
Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial.
    JAMA oncology, 2022, 08-01, Volume: 8, Issue:8

    Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Receptor, ErbB-2

2022
nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2- metastatic breast cancer.
    Breast cancer research and treatment, 2022, Volume: 195, Issue:1

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Humans; Progression-Free Survival; Tamoxifen

2022
An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer.
    Breast cancer research and treatment, 2022, Volume: 195, Issue:3

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Diarrhea; Female; Humans; Loperamide

2022
Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial.
    European journal of cancer (Oxford, England : 1990), 2022, Volume: 174

    Topics: Aminopyridines; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Purines; Quality of Life; Taxoids

2022
Abemaciclib plus fulvestrant in East Asian women with HR+, HER2- advanced breast cancer: Overall survival from MONARCH 2.
    Cancer science, 2023, Volume: 114, Issue:1

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; East Asian People; Female; Fulvestrant; Humans; Receptor, ErbB-2

2023
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2- advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial.
    Breast (Edinburgh, Scotland), 2022, Volume: 66

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Neutropenia; Protein Kinase Inhibitors; Receptor, ErbB-2

2022
Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1.
    The oncologist, 2023, 01-18, Volume: 28, Issue:1

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Humans; Protein Kinase Inhibitors; Receptor, ErbB-2

2023
Justifying Ribociclib Dose in Patients with Advanced Breast Cancer with Renal Impairment Based on PK, Safety, and Efficacy Data: An Innovative Approach Integrating Data from a Dedicated Renal Impairment Study and Oncology Clinical Trials.
    Clinical pharmacokinetics, 2023, Volume: 62, Issue:3

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Purines; Renal Insufficiency

2023
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial.
    European journal of cancer (Oxford, England : 1990), 2023, Volume: 186

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Female; Humans; Letrozole; Proportional Hazards Models; Prospective Studies; Receptor, ErbB-2; Thymidine Kinase

2023
Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.
    International journal of cancer, 2023, 10-01, Volume: 153, Issue:7

    Topics: Aminopyridines; Australia; Breast Neoplasms; Cyclin D; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclins; DNA Helicases; Female; Humans; Neoplasms; Nuclear Proteins; Precision Medicine; Protein Kinase Inhibitors

2023
Potential value of ctDNA monitoring in metastatic HR + /HER2 - breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial.
    BMC medicine, 2023, 08-15, Volume: 21, Issue:1

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Receptor, ErbB-2

2023
Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA).
    Breast (Edinburgh, Scotland), 2023, Volume: 72

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Quality of Life; Receptor, ErbB-2

2023
Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial).
    Journal for immunotherapy of cancer, 2023, Volume: 11, Issue:9

    Topics: Aminopyridines; Antibodies; Benzimidazoles; Breast Neoplasms; Female; Humans; Letrozole; Nivolumab

2023
Abemaciclib, a potent cyclin-dependent kinase 4 and 6 inhibitor, for treatment of ER-positive metastatic breast cancer.
    Future oncology (London, England), 2019, Volume: 15, Issue:29

    Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Evaluation; Female; Follow-Up Studies; Humans; Mice; Molecular Targeted Therapy; Neoplasm Metastasis; Piperazines; Prognosis; Purines; Pyridines; Receptors, Estrogen; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2019
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
    JAMA oncology, 2020, Jan-01, Volume: 6, Issue:1

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Middle Aged; Receptor, ErbB-2; Triple Negative Breast Neoplasms

2020
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.
    The New England journal of medicine, 2020, 02-06, Volume: 382, Issue:6

    Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; Middle Aged; Postmenopause; Progression-Free Survival; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone

2020
Cyclin-dependent kinase inhibitors plus aromatase inhibitor in first-line treatment hormone-receptor-positive/HER2-negative advanced breast cancer women with or without visceral disease: time to turn page?
    Anti-cancer drugs, 2020, Volume: 31, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Follow-Up Studies; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Piperazines; Prognosis; Purines; Pyridines; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Viscera

2020
Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy.
    The oncologist, 2020, Volume: 25, Issue:2

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen

2020
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
    The Lancet. Oncology, 2020, Volume: 21, Issue:6

    Topics: Aged; Aminopyridines; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Argentina; Australia; Benzimidazoles; Brazil; Breast Neoplasms; Disease Progression; Estrogen Receptor Antagonists; Europe; Female; Fulvestrant; Humans; Middle Aged; North America; Progression-Free Survival; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Republic of Korea; Signal Transduction; Time Factors; Trastuzumab

2020
Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer.
    The oncologist, 2020, Volume: 25, Issue:9

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Female; Humans; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen

2020
Development and Application of a Mechanistic Population Modeling Approach to Describe Abemaciclib Pharmacokinetics.
    CPT: pharmacometrics & systems pharmacology, 2020, Volume: 9, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Case-Control Studies; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Compounding; Drug Development; Female; Humans; Male; Middle Aged; Nonlinear Dynamics; Protein Kinase Inhibitors

2020
A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 10-15, Volume: 26, Issue:20

    Topics: Adult; Aged; Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain Neoplasms; Breast Neoplasms; Disease-Free Survival; Female; Humans; Mice; Middle Aged; Protein Kinase Inhibitors; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab

2020
Evaluation of Absolute Oral Bioavailability and Bioequivalence of Ribociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, in Healthy Subjects.
    Clinical pharmacology in drug development, 2020, Volume: 9, Issue:7

    Topics: Administration, Oral; Adult; Aminopyridines; Biological Availability; Breast Neoplasms; Cross-Over Studies; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Compounding; Female; Healthy Volunteers; Humans; Infusions, Intravenous; Male; Middle Aged; Purines; Receptor, ErbB-2; Safety; Severity of Illness Index; Therapeutic Equivalency

2020
Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy.
    Journal of the National Cancer Institute, 2021, 04-06, Volume: 113, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Benzimidazoles; Body Mass Index; Breast Neoplasms; Confidence Intervals; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Middle Aged; Neutropenia; Obesity; Odds Ratio; Overweight; Placebos; Progression-Free Survival; Thinness; Weight Loss

2021
    Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2022, Volume: 30, Issue:2

    Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea

2022
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 12-01, Volume: 38, Issue:34

    Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Young Adult

2020
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study.
    Breast (Edinburgh, Scotland), 2020, Volume: 54

    Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Fulvestrant; Health Status; Humans; Kaplan-Meier Estimate; Middle Aged; Patient Reported Outcome Measures; Progression-Free Survival; Proportional Hazards Models; Purines; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone

2020
nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer.
    Clinical breast cancer, 2021, Volume: 21, Issue:3

    Topics: Adult; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Metastasis; Prognosis; Progression-Free Survival; Tamoxifen; Treatment Outcome

2021
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials.
    Breast cancer research and treatment, 2021, Volume: 186, Issue:2

    Topics: Age Factors; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Receptor, ErbB-2

2021
Abemaciclib Improves Disease-Free Survival in High-Risk HR+/HER2- Early Breast Cancer.
    The oncologist, 2021, Volume: 26 Suppl 2

    Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Disease-Free Survival; Female; Humans; Receptor, ErbB-2

2021
Drug shows significant early promise in early, high-risk, HR-positive, HER2-negative breast cancer: Interim data indicate that adding abemaciclib to hormonal therapy reduces recurrence risk.
    Cancer, 2021, 01-15, Volume: 127, Issue:2

    Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease-Free Survival; Drug Therapy, Combination; Female; Hormone Replacement Therapy; Humans; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptors, Estrogen

2021
Pharmacokinetics of Ribociclib in Subjects With Hepatic Impairment.
    Journal of clinical pharmacology, 2021, Volume: 61, Issue:8

    Topics: Aminopyridines; Antineoplastic Agents; Area Under Curve; Breast Neoplasms; Female; Half-Life; Humans; Liver Diseases; Male; Metabolic Clearance Rate; Middle Aged; Patient Acuity; Purines

2021
First-line Treatment with Ribociclib plus Endocrine Therapy for Premenopausal Women with Hormone-receptor-positive Advanced Breast Cancer: A Cost-effectiveness Analysis.
    Clinical breast cancer, 2021, Volume: 21, Issue:4

    Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Breast Neoplasms; China; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Humans; Markov Chains; Premenopause; Purines; Quality-Adjusted Life Years; Receptor, ErbB-2; United States

2021
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.
    Cancer science, 2021, Volume: 112, Issue:6

    Topics: Aminopyridines; Anastrozole; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Female; Fulvestrant; Humans; Letrozole; Neutropenia; Receptor, ErbB-2; Treatment Outcome

2021
Ribociclib Population Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Analysis of Neutrophils in Cancer Patients.
    Journal of clinical pharmacology, 2021, Volume: 61, Issue:8

    Topics: Adult; Age Factors; Aged; Aminopyridines; Antineoplastic Agents; Area Under Curve; Body Weight; Breast Neoplasms; Drug Interactions; Female; Humans; Kidney Function Tests; Liver Function Tests; Male; Metabolic Clearance Rate; Metabolic Networks and Pathways; Middle Aged; Models, Biological; Neoplasm Metastasis; Neutrophils; Purines; Racial Groups; Receptor, ErbB-2; Receptors, Progesterone; Sex Factors

2021
Patient-Reported Outcomes Predict Progression-Free Survival of Patients with Advanced Breast Cancer Treated with Abemaciclib.
    The oncologist, 2021, Volume: 26, Issue:7

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Humans; Patient Reported Outcome Measures; Progression-Free Survival; Receptor, ErbB-2

2021
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2021, Volume: 32, Issue:8

    Topics: Adolescent; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Fulvestrant; Humans; Postmenopause; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone

2021
Ribociclib Shows Sustained Overall Survival Benefit in Postmenopausal Women with HR+/HER2- Advanced Breast Cancer.
    The oncologist, 2021, Volume: 26 Suppl 3

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Postmenopause; Purines; Receptor, ErbB-2; Receptors, Progesterone

2021
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer.
    British journal of cancer, 2021, Volume: 125, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Drug Tapering; Female; Humans; Middle Aged; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Young Adult

2021
Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy.
    EBioMedicine, 2021, Volume: 69

    Topics: Adult; Aged; Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; MCF-7 Cells; Menopause; Middle Aged; Neoadjuvant Therapy; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Transcriptome

2021
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
    Breast cancer research and treatment, 2021, Volume: 189, Issue:3

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Letrozole; Purines; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone

2021
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
    Breast cancer research : BCR, 2021, 08-23, Volume: 23, Issue:1

    Topics: Adult; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Middle Aged; Premenopause; Progression-Free Survival; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Response Evaluation Criteria in Solid Tumors; Survival Rate

2021
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    The Lancet. Oncology, 2017, Volume: 18, Issue:7

    Topics: Aged; Alanine Transaminase; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; Double-Blind Method; Drug Eruptions; Estradiol; Exanthema; Female; Fulvestrant; Humans; Hyperglycemia; Middle Aged; Morpholines; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Response Evaluation Criteria in Solid Tumors; Retreatment; Signal Transduction; Survival Rate

2017
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Sep-01, Volume: 35, Issue:25

    Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease-Free Survival; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone

2017
Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 85

    Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Australia; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Class I Phosphatidylinositol 3-Kinases; Double-Blind Method; Early Termination of Clinical Trials; Europe; Female; Humans; Ki-67 Antigen; Lymphocytes, Tumor-Infiltrating; Middle Aged; Morpholines; Mutation; Neoadjuvant Therapy; Paclitaxel; Protein Kinase Inhibitors; Receptor, ErbB-2; Time Factors; Trastuzumab; Treatment Outcome

2017
PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 86

    Topics: Administration, Oral; Adult; Aged; Aminopyridines; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Drug Dosage Calculations; Drug Resistance, Neoplasm; Female; France; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Morpholines; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome

2017
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Nov-10, Volume: 35, Issue:32

    Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzimidazoles; Biomarkers, Tumor; Breast Neoplasms; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptor, ErbB-2; Survival Rate; Treatment Outcome; Triazoles

2017
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.
    Breast cancer research and treatment, 2018, Volume: 167, Issue:3

    Topics: Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Letrozole; Middle Aged; Nitriles; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triazoles

2018
A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer.
    Clinical breast cancer, 2018, Volume: 18, Issue:4

    Topics: Adult; Aminopyridines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Middle Aged; Morpholines; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Treatment Outcome

2018
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.
    Breast cancer research and treatment, 2018, Volume: 168, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Chemotherapy-Induced Febrile Neutropenia; Female; Humans; Incidence; Kaplan-Meier Estimate; Letrozole; Leukopenia; Middle Aged; Postmenopause; Progression-Free Survival; Purines; Receptors, Estrogen; Receptors, Progesterone; Response Evaluation Criteria in Solid Tumors; Time Factors

2018
Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy.
    Breast cancer research and treatment, 2018, Volume: 168, Issue:2

    Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Capecitabine; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Maximum Tolerated Dose; Middle Aged; Morpholines; Receptor, ErbB-2; Response Evaluation Criteria in Solid Tumors; Trastuzumab

2018
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
    The Lancet. Oncology, 2018, Volume: 19, Issue:1

    Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease Progression; Disease-Free Survival; Double-Blind Method; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Middle Aged; Morpholines; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome

2018
First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial.
    Breast cancer research and treatment, 2018, Volume: 169, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Kaplan-Meier Estimate; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Purines; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Young Adult

2018
Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2.
    Breast cancer research and treatment, 2018, Volume: 170, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Postmenopause; Purines; Quality of Life; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Young Adult

2018
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 07-01, Volume: 29, Issue:7

    Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Double-Blind Method; Female; Follow-Up Studies; Humans; Letrozole; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Recurrence, Local; Prognosis; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate

2018
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
    The Lancet. Oncology, 2018, Volume: 19, Issue:7

    Topics: Administration, Oral; Adult; Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Humans; Internationality; Kaplan-Meier Estimate; Letrozole; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Premenopause; Prognosis; Proportional Hazards Models; Purines; Survival Analysis; Tamoxifen; Treatment Outcome; Young Adult

2018
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 08-20, Volume: 36, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; Middle Aged; Progression-Free Survival; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone

2018
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.
    European journal of cancer (Oxford, England : 1990), 2018, Volume: 103

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Fulvestrant; Humans; Middle Aged; Morpholines; Postmenopause; Survival Analysis

2018
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    The Lancet. Oncology, 2019, Volume: 20, Issue:6

    Topics: Aminopyridines; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Breast Neoplasms; Double-Blind Method; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Salvage Therapy; Survival Rate; Treatment Outcome

2019
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.
    The New England journal of medicine, 2019, 07-25, Volume: 381, Issue:4

    Topics: Adult; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cyclin-Dependent Kinases; Double-Blind Method; Female; Follow-Up Studies; Humans; Intention to Treat Analysis; Middle Aged; Perimenopause; Premenopause; Protein Kinase Inhibitors; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Tamoxifen

2019
Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial.
    Clinical breast cancer, 2019, Volume: 19, Issue:6

    Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Female; Follow-Up Studies; Humans; Middle Aged; Prognosis; Purines; Receptor, ErbB-2; Survival Rate; Trastuzumab

2019
MONALEESA clinical program: a review of ribociclib use in different clinical settings.
    Future oncology (London, England), 2019, Volume: 15, Issue:23

    Topics: Adolescent; Adult; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estrogens; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Postmenopause; Progression-Free Survival; Purines; Receptor, ErbB-2; Tamoxifen; Young Adult

2019
Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Apr-20, Volume: 32, Issue:12

    Topics: Adult; Aged; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Humans; Letrozole; Middle Aged; Morpholines; Multimodal Imaging; Nitriles; Phosphoinositide-3 Kinase Inhibitors; Positron-Emission Tomography; Protein Kinase Inhibitors; Radiopharmaceuticals; Receptor, ErbB-2; Receptors, Estrogen; Tomography, X-Ray Computed; Triazoles

2014
LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.
    The Journal of clinical investigation, 2014, Volume: 124, Issue:12

    Topics: Amino Acid Substitution; Aminopyridines; Animals; Breast Neoplasms; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; Estrogen Receptor Modulators; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Morpholines; Mutation, Missense; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Receptors, Estrogen; src Homology Domains; src-Family Kinases; Thiazoles; Xenograft Model Antitumor Assays

2014
Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.
    Breast (Edinburgh, Scotland), 2016, Volume: 28

    Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin D2; Cyclin D3; Cyclin E; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; DNA, Neoplasm; Female; Gene Expression; Humans; Ki-67 Antigen; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Oncogene Proteins; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retinoblastoma Protein; Signal Transduction; Triazoles

2016
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
    The New England journal of medicine, 2016, 11-03, Volume: 375, Issue:18

    Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triazoles

2016
A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 02-01, Volume: 28, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Morpholines; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Proportional Hazards Models; Receptor, ErbB-2; Treatment Outcome; Young Adult

2017
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 03-01, Volume: 28, Issue:3

    Topics: Adult; Aged; Aminopyridines; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Germ-Line Mutation; Humans; Middle Aged; Morpholines; Neoplasm Grading; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases

2017

Other Studies

204 other study(ies) available for alpha-aminopyridine and Breast Cancer

ArticleYear
Assessment of Transporter-Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients With Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.
    Journal of clinical pharmacology, 2022, Volume: 62, Issue:4

    Topics: Aged; Aminopyridines; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Digoxin; Drug Interactions; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Membrane Transport Proteins; Myelodysplastic Syndromes; Neoplasm Proteins; Pharmaceutical Preparations; Recurrence; Rosuvastatin Calcium; Triazines

2022
Safety of cyclin-dependent kinase4/6 inhibitor combined with palliative radiotherapy in patients with metastatic breast cancer.
    Breast (Edinburgh, Scotland), 2021, Volume: 60

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Piperazines; Protein Kinase Inhibitors; Pyridines; Retrospective Studies

2021
[A Case of Advanced Late Recurrence of Hormone Receptor Positive Breast Cancer Successfully Treated with Abemaciclib and Anastrozole].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2021, Volume: 48, Issue:10

    Topics: Aged; Aminopyridines; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Female; Hormones; Humans; Neoplasm Recurrence, Local; Nitriles

2021
Peritoneal Metastasis After Treated With Abemaciclib Plus Fulvestrant for Metastatic Invasive Lobular Breast Cancer: A Case Report and Review of the Literature.
    Frontiers in endocrinology, 2021, Volume: 12

    Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Fatal Outcome; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Peritoneal Neoplasms

2021
A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2021, Nov-15, Volume: 1185

    Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Chromatography, Liquid; Dried Blood Spot Testing; Drug Monitoring; Female; Humans; Letrozole; Piperazines; Purines; Pyridines; Tandem Mass Spectrometry

2021
Lactic acidosis, a potential toxicity from drug-drug interaction related to concomitant ribociclib and metformin in preexisting renal insufficiency: A case report.
    Cancer reports (Hoboken, N.J.), 2022, Volume: 5, Issue:8

    Topics: Acidosis, Lactic; Aminopyridines; Breast Neoplasms; Drug Interactions; Female; Fulvestrant; Humans; Metformin; Middle Aged; Purines; Renal Insufficiency

2022
Letter to the Editor for 'Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study'.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2022, Volume: 33, Issue:2

    Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Female; Humans; Ki-67 Antigen

2022
Abemaciclib is a potent inhibitor of DYRK1A and HIP kinases involved in transcriptional regulation.
    Nature communications, 2021, 11-16, Volume: 12, Issue:1

    Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Carrier Proteins; Crystallography, X-Ray; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Dyrk Kinases; Female; Gene Expression Regulation; Humans; Intracellular Signaling Peptides and Proteins; Phosphorylation; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Ribosomal Proteins; RNA-Binding Proteins; Signal Transduction

2021
Adjuvant abemaciclib for high-risk breast cancer: the story continues.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2021, Volume: 32, Issue:12

    Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Female; Humans

2021
Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2022, Volume: 33, Issue:3

    Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Humans; Ki-67 Antigen

2022
Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trial.
    European journal of cancer (Oxford, England : 1990), 2022, Volume: 162

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Immunity; Leukocytes, Mononuclear; Purines; Receptor, ErbB-2

2022
Amalgamated Microneedle Array Bearing Ribociclib-Loaded Transfersomes Eradicates Breast Cancer
    Biomacromolecules, 2022, 03-14, Volume: 23, Issue:3

    Topics: Aminopyridines; Breast Neoplasms; Drug Delivery Systems; Female; Humans; Hyaluronan Receptors; Purines

2022
FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 04-10, Volume: 40, Issue:11

    Topics: Adult; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Disease-Free Survival; Female; Humans; Ki-67 Antigen; Receptor, ErbB-2

2022
Subsequent-abemaciclib Treatment After Disease Progression on Palbociclib in Patients With ER-positive HER2-negative Metastatic Breast Cancer.
    Anticancer research, 2022, Volume: 42, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Japan; Middle Aged; Neoplasm Metastasis; Piperazines; Progression-Free Survival; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Treatment Outcome

2022
In brief: Abemaciclib (Verzenio) for early breast cancer.
    The Medical letter on drugs and therapeutics, 2021, 12-13, Volume: 63, Issue:1639

    Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Female; Humans

2021
Ribociclib Nanostructured Lipid Carrier Aimed for Breast Cancer: Formulation Optimization, Attenuating
    BioMed research international, 2022, Volume: 2022

    Topics: Administration, Oral; Aminopyridines; Animals; Biological Availability; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Excipients; Female; Intestinal Absorption; Nanostructures; Purines; Rats; Rats, Wistar

2022
Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment.
    International journal of molecular sciences, 2022, Feb-24, Volume: 23, Issue:5

    Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinase Inhibitor Proteins; Female; Humans; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Tumor Microenvironment

2022
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2022, Volume: 33, Issue:6

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Receptor, ErbB-2

2022
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2022, Volume: 33, Issue:6

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Diarrhea; Female; Humans; Neoplasm Recurrence, Local; Patient Reported Outcome Measures; Quality of Life; Receptor, ErbB-2

2022
Ribociclib Improves Overall Survival in HR+/HER2- Metastatic Breast Cancer Across Common Genomic and Clinical Subtypes.
    The oncologist, 2022, 03-28, Volume: 27, Issue:Suppl 1

    Topics: Aminopyridines; Breast Neoplasms; Female; Genomics; Humans; Purines

2022
Adjuvant Abemaciclib Plus Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A.
    JCO oncology practice, 2022, Volume: 18, Issue:7

    Topics: Aminopyridines; Benzimidazoles; Breast; Breast Neoplasms; Female; Humans

2022
Clinical and pathological features of breast cancer patients eligible for adjuvant abemaciclib.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2022, Volume: 33, Issue:8

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Humans

2022
Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study.
    BMC cancer, 2022, May-07, Volume: 22, Issue:1

    Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Drug Interactions; Female; Fulvestrant; Humans; Letrozole; Piperazines; Protein Kinase Inhibitors; Proton Pump Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Retrospective Studies

2022
Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclib.
    European journal of clinical pharmacology, 2022, Volume: 78, Issue:8

    Topics: Aminopyridines; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Benzimidazoles; Breast Neoplasms; Female; Genotype; Humans; Polymorphism, Single Nucleotide

2022
Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women.
    Applied health economics and health policy, 2022, Volume: 20, Issue:4

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Female; Fulvestrant; Humans; Paclitaxel; Piperazines; Postmenopause; Purines; Pyridines

2022
Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
    Current medical research and opinion, 2022, Volume: 38, Issue:8

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Incidence; Protein Kinase Inhibitors; Retrospective Studies; United States

2022
Vortex keratopathy associated with ribociclib.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2023, Volume: 29, Issue:1

    Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Purines; Receptor, ErbB-2

2023
[A Case of Postoperative Pulmonary Metastasis of Breast Cancer with Complete Response by Abemaciclib plus Fulvestrant Therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2022, Volume: 49, Issue:5

    Topics: Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Lung Neoplasms; Mastectomy; Neoplasm Recurrence, Local

2022
Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2- high-risk breast cancer.
    Expert review of anticancer therapy, 2022, Volume: 22, Issue:8

    Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Protein Kinase Inhibitors; Receptor, ErbB-2

2022
Venous and arterial thrombosis associated with abemaciclib therapy for metastatic breast cancer.
    Cancer, 2022, 09-01, Volume: 128, Issue:17

    Topics: Aminopyridines; Anticoagulants; Benzimidazoles; Breast Neoplasms; Female; Humans; Thrombosis; Venous Thromboembolism

2022
Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation.
    Oncotarget, 2022, Volume: 13

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors

2022
CDK4/6 inhibitors downregulate the ubiquitin-conjugating enzymes UBE2C/S/T involved in the ubiquitin-proteasome pathway in ER + breast cancer.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2022, Volume: 24, Issue:11

    Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Hormones; Humans; Phosphatidylinositol 3-Kinases; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Purines; RNA, Messenger; Ubiquitin-Conjugating Enzymes; Ubiquitins

2022
Abemaciclib and Fulvestrant for Bilateral Choroidal Metastasis From Breast Carcinoma.
    JAMA ophthalmology, 2022, 10-01, Volume: 140, Issue:10

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans

2022
Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2- Advanced Breast Cancer Patients: An Italian Managed Access Program.
    Current oncology (Toronto, Ont.), 2022, 09-17, Volume: 29, Issue:9

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Gonadotropin-Releasing Hormone; Humans; Purines; Receptor, ErbB-2; Receptors, Estrogen

2022
Quantifying Clinical Utility of Adjuvant Abemaciclib in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy-Reply.
    JAMA oncology, 2022, 11-01, Volume: 8, Issue:11

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Neoadjuvant Therapy; Receptor, ErbB-2

2022
Quantifying Clinical Utility of Adjuvant Abemaciclib in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy.
    JAMA oncology, 2022, 11-01, Volume: 8, Issue:11

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Neoadjuvant Therapy; Receptor, ErbB-2

2022
The Cyclin-Dependent Kinase 4/6 Inhibitor Abemaciclib Is Tolerated Better than Palbociclib by Advanced Breast Cancer Patients with High Serum Albumin Levels.
    Biological & pharmaceutical bulletin, 2022, Volume: 45, Issue:10

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Retrospective Studies; Serum Albumin

2022
Absolute Lymphocyte Count Is an Independent Prognostic Factor for ER-positive HER2-negative Advanced Breast Cancer Patients Treated With CDK4/6 Inhibitors.
    Anticancer research, 2022, Volume: 42, Issue:10

    Topics: Aminopyridines; Benzimidazoles; Biomarkers; Breast Neoplasms; C-Reactive Protein; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Lymphocyte Count; Lymphocytes; Prognosis; Protein Kinase Inhibitors; Receptors, Estrogen; Retrospective Studies

2022
Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study.
    Breast (Edinburgh, Scotland), 2022, Volume: 66

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Receptor, ErbB-2

2022
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib.
    Breast (Edinburgh, Scotland), 2022, Volume: 66

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Estrogens; Female; Humans; Proton Pump Inhibitors; Retrospective Studies

2022
Clinical features of CDK4/6 inhibitor-related interstitial lung disease in patients with breast cancer: a case series study.
    Japanese journal of clinical oncology, 2023, Jan-28, Volume: 53, Issue:2

    Topics: Aminopyridines; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Middle Aged; Protein Kinase Inhibitors; Retrospective Studies

2023
The effect of concomitant use of proton pump inhibitors with CDK 4/6 inhibitors on survival in metastatic breast cancer.
    European journal of clinical pharmacology, 2023, Volume: 79, Issue:2

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Protein Kinase Inhibitors; Proton Pump Inhibitors; Purines

2023
[Expert consensus on the management of adverse events of CDK4/6 inhibitors in breast cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2022, Dec-23, Volume: 44, Issue:12

    Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Consensus; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Protein Kinase Inhibitors

2022
Therapeutic drug monitoring in breast cancer therapy - LC-MS/MS method for quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, ribociclib, and major metabolites abemaciclib M20 and M2 in human serum.
    Journal of pharmaceutical and biomedical analysis, 2023, Feb-20, Volume: 225

    Topics: Aminopyridines; Breast Neoplasms; Chromatography, Liquid; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Monitoring; Female; Humans; Protein Kinase Inhibitors; Tandem Mass Spectrometry

2023
Ribociclib-induced hepatotoxicity.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2023, Volume: 29, Issue:5

    Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Protein Kinase Inhibitors; Purines

2023
Abemaciclib-associated Diarrhea: An Exploratory Analysis of Real-life Data.
    Anticancer research, 2023, Volume: 43, Issue:3

    Topics: Aged; Aminopyridines; Benzimidazoles; Breast Neoplasms; Diarrhea; Female; Humans

2023
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer.
    The Lancet. Oncology, 2023, Volume: 24, Issue:3

    Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Female; Humans; Immunologic Factors

2023
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer - Authors' reply.
    The Lancet. Oncology, 2023, Volume: 24, Issue:3

    Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Female; Humans; Immunologic Factors

2023
Characteristics and Outcomes in Cases of US Male Patients with Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice.
    Advances in therapy, 2023, Volume: 40, Issue:5

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Fulvestrant; Humans; Male; Receptor, ErbB-2; Retrospective Studies

2023
In brief: A new indication for abemaciclib (Verzenio).
    The Medical letter on drugs and therapeutics, 2023, 04-03, Volume: 65, Issue:1673

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Humans; Receptor, ErbB-2

2023
US Food and Drug Administration Expanded Adjuvant Indication of Abemaciclib in High-Risk Early Breast Cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 06-20, Volume: 41, Issue:18

    Topics: Adjuvants, Immunologic; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Pyridines; United States; United States Food and Drug Administration

2023
Letter to the Editor: statistics and clinical perception of patients' reported outcomes for palbociclib and abemaciclib: a sliding doors story.
    Journal of comparative effectiveness research, 2023, Volume: 12, Issue:6

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Perception; Pyridines

2023
Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer - Authors' reply.
    The Lancet. Oncology, 2023, Volume: 24, Issue:6

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Humans

2023
Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer.
    The Lancet. Oncology, 2023, Volume: 24, Issue:6

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Humans; Receptor, ErbB-2

2023
Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR + , HER2- metastatic breast cancer patients in Japan.
    Breast cancer (Tokyo, Japan), 2023, Volume: 30, Issue:4

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Japan; Middle Aged; Receptor, ErbB-2

2023
Clinical Management of Potential Toxicity of Abemaciclib and Approaches to Ensure Treatment Continuation.
    Asian Pacific journal of cancer prevention : APJCP, 2023, Jun-01, Volume: 24, Issue:6

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Humans; Neutropenia; Treatment Outcome

2023
Quantitative Assessment of Ribociclib Exposure-Response Relationship to Justify Dose Regimen in Patients with Advanced Breast Cancer.
    Journal of clinical pharmacology, 2023, Volume: 63, Issue:12

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Neutropenia; Purines; Receptor, ErbB-2

2023
[ESR1 Mutation-Positive Recurrent Breast Cancer Successfully Treated with Letrozole plus Abemaciclib].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2023, Volume: 50, Issue:8

    Topics: Aminopyridines; Breast Neoplasms; Female; Humans; Letrozole; Mutation

2023
Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2023, Volume: 34, Issue:11

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Letrozole; Prospective Studies; Receptor, ErbB-2

2023
CDK 4/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases.
    Journal of neuro-oncology, 2019, Volume: 144, Issue:3

    Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease Management; Female; Follow-Up Studies; Humans; Middle Aged; Piperazines; Prognosis; Pyridines; Radiosurgery; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate

2019
Phosphorylation of HSF1 by PIM2 Induces PD-L1 Expression and Promotes Tumor Growth in Breast Cancer.
    Cancer research, 2019, Oct-15, Volume: 79, Issue:20

    Topics: Aminopyridines; Animals; Autophagy; B7-H1 Antigen; Benzylidene Compounds; Breast Neoplasms; Carboplatin; F-Box-WD Repeat-Containing Protein 7; Female; Gene Expression Regulation, Neoplastic; Heat Shock Transcription Factors; Humans; Indazoles; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Neoplasm Proteins; Phosphorylation; Protein Binding; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Stability; Proto-Oncogene Proteins; RNA Interference; RNA, Small Interfering; Substrate Specificity; Thiazolidinediones; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays

2019
Toxic epidermal necrolysis associated with ribociclib in a patient with metastatic breast cancer.
    The breast journal, 2020, Volume: 26, Issue:4

    Topics: Aminopyridines; Breast Neoplasms; Female; Humans; Purines; Stevens-Johnson Syndrome

2020
CDK 4/6 inhibitor successful rechallenge after limiting hepatic toxicity.
    The breast journal, 2020, Volume: 26, Issue:2

    Topics: Alanine Transaminase; Aminopyridines; Aromatase Inhibitors; Aspartate Aminotransferases; Bone Neoplasms; Breast Neoplasms; Carcinoma, Lobular; Chemical and Drug Induced Liver Injury; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Substitution; Drug Therapy, Combination; Female; Humans; Letrozole; Middle Aged; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines

2020
[Pharmacological Effects of CDK4 & 6 Selective Inhibitor Abemaciclib in Hormone Receptor-Positive Breast Cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:9

    Topics: Aminopyridines; Animals; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Humans; Protein Kinase Inhibitors

2019
Abemaciclib plus fulvestrant for breast cancer.
    The Lancet. Oncology, 2019, Volume: 20, Issue:11

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Clinical Trials, Phase III as Topic; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Progression-Free Survival; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic

2019
CDK4/6 inhibitors prolong OS.
    Nature reviews. Clinical oncology, 2019, Volume: 16, Issue:12

    Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Fulvestrant; Humans; Receptor, ErbB-2

2019
Palbociclib safety and efficacy beyond Ribociclib-induced liver toxicity in metastatic hormone-receptors positive breast cancer patient.
    Anti-cancer drugs, 2020, Volume: 31, Issue:1

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Female; Humans; Letrozole; Liver; Middle Aged; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptors, Estrogen; Receptors, Progesterone; Zoledronic Acid

2020
Ribociclib and Endocrine Therapy in Breast Cancer.
    The New England journal of medicine, 2019, 10-17, Volume: 381, Issue:16

    Topics: Aminopyridines; Breast Neoplasms; Humans; Purines

2019
Ribociclib and Endocrine Therapy in Breast Cancer. Reply.
    The New England journal of medicine, 2019, 10-17, Volume: 381, Issue:16

    Topics: Aminopyridines; Breast Neoplasms; Humans; Purines

2019
Association between ribociclib and changes in creatinine in patients with hormone receptor positive metastatic breast cancer.
    Internal medicine journal, 2019, Volume: 49, Issue:11

    Topics: Aged; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Creatinine; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; New South Wales; Purines; Receptor, ErbB-2; Retrospective Studies

2019
Time for a shift in molecular down staging in luminal breast cancer.
    The Lancet. Oncology, 2020, Volume: 21, Issue:1

    Topics: Aminopyridines; Breast Neoplasms; Female; Humans; Letrozole; Postmenopause; Purines; Receptor, ErbB-2; Receptors, Progesterone

2020
Glucose restriction reverses the Warburg effect and modulates PKM2 and mTOR expression in breast cancer cell lines.
    Cellular and molecular biology (Noisy-le-Grand, France), 2019, Sep-30, Volume: 65, Issue:7

    Topics: Adenosine Triphosphate; Aminopyridines; Blotting, Western; Breast Neoplasms; Carrier Proteins; Cell Line, Tumor; Colorimetry; Down-Regulation; Flow Cytometry; Glucose; Humans; Lactic Acid; MCF-7 Cells; Membrane Proteins; Piperidines; Thyroid Hormone-Binding Proteins; Thyroid Hormones; TOR Serine-Threonine Kinases

2019
Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway.
    EMBO molecular medicine, 2020, 02-07, Volume: 12, Issue:2

    Topics: Aminopyridines; Animals; Breast Neoplasms; Culture Media, Conditioned; Epithelial Cells; Female; Humans; I-kappa B Kinase; Inflammation; Macrophages; Mammary Glands, Human; Mice; Obesity; Protein Serine-Threonine Kinases; Serine

2020
[Ribociclib in combination with endocrine therapy improves overall survival of pre-/perimenopausal breast cancer patients].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2020, Volume: 196, Issue:3

    Topics: Aminopyridines; Breast Neoplasms; Humans; Perimenopause; Purines

2020
Cdk4 and Cdk6 Couple the Cell-Cycle Machinery to Cell Growth via mTORC1.
    Cell reports, 2020, 04-14, Volume: 31, Issue:2

    Topics: Aminopyridines; Animals; Benzimidazoles; Breast Neoplasms; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Proliferation; Cyclin D; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Humans; Mechanistic Target of Rapamycin Complex 1; Mice; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyridines; Tuberous Sclerosis Complex 2 Protein

2020
CDK4/6 inhibition in HER2-positive breast cancer.
    The Lancet. Oncology, 2020, Volume: 21, Issue:6

    Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Fulvestrant; Humans; Trastuzumab

2020
Treatment options for patients with HR+/HER2- advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy.
    Breast cancer research and treatment, 2020, Volume: 182, Issue:1

    Topics: Aminopyridines; Betacoronavirus; Breast Neoplasms; Coronavirus Infections; COVID-19; Humans; Pandemics; Pneumonia, Viral; Purines; SARS-CoV-2; Triage

2020
Response to the article by Dietz et al. entitled "Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID‑19 pandemic. The COVID‑19 pandemic breast cancer consortium".
    Breast cancer research and treatment, 2020, Volume: 182, Issue:2

    Topics: Aminopyridines; Betacoronavirus; Breast Neoplasms; Coronavirus Infections; COVID-19; Humans; Pandemics; Pneumonia, Viral; Purines; SARS-CoV-2; Triage

2020
Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer.
    JAMA oncology, 2020, 07-01, Volume: 6, Issue:7

    Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Fulvestrant; Humans; Receptor, ErbB-2

2020
Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer.
    JAMA oncology, 2020, 07-01, Volume: 6, Issue:7

    Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Fulvestrant; Humans; Receptor, ErbB-2

2020
Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer-Reply.
    JAMA oncology, 2020, 07-01, Volume: 6, Issue:7

    Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Fulvestrant; Humans; Receptor, ErbB-2

2020
Ribociclib plus Fulvestrant in Advanced Breast Cancer.
    The New England journal of medicine, 2020, 06-04, Volume: 382, Issue:23

    Topics: Aminopyridines; Breast Neoplasms; Fulvestrant; Humans; Purines

2020
Ribociclib plus Fulvestrant in Advanced Breast Cancer. Reply.
    The New England journal of medicine, 2020, 06-04, Volume: 382, Issue:23

    Topics: Aminopyridines; Breast Neoplasms; Fulvestrant; Humans; Purines

2020
Henoch-schönlein Purpura (HSP) in a patient on Abemaciclib.
    Breast (Edinburgh, Scotland), 2020, Volume: 52

    Topics: Aged; Aminopyridines; Benzimidazoles; Breast Neoplasms; Female; Humans; IgA Vasculitis

2020
Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer.
    Cancer science, 2020, Volume: 111, Issue:9

    Topics: Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Japan; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Purines; Treatment Outcome

2020
Cyclin-Dependent Kinase 4/6 Inhibitors Combined With Radiotherapy for Patients With Metastatic Breast Cancer.
    Clinical breast cancer, 2020, Volume: 20, Issue:6

    Topics: Adult; Aged; Aminopyridines; Benzimidazoles; Breast Neoplasms; Cancer Pain; Chemoradiotherapy; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Organs at Risk; Pain Measurement; Palliative Care; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Radiotherapy Dosage; Treatment Outcome

2020
Ribociclib therapy in peritoneal carcinomatosis secondary to HER2-negative metastatic breast cancer: A clinical case with a positive outcome.
    The breast journal, 2020, Volume: 26, Issue:9

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Peritoneal Neoplasms; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone

2020
A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 01-15, Volume: 27, Issue:2

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Goserelin; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Receptor, ErbB-2; Tamoxifen; Thiazoles

2021
Autophagic Vacuole Secretion Triggered by Chidamide Participates in TRAIL Apoptosis Effect in Breast Cancer Cells.
    Current pharmaceutical design, 2021, Volume: 27, Issue:20

    Topics: Aminopyridines; Apoptosis; Autophagosomes; Benzamides; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Histone Deacetylase Inhibitors; Humans; TNF-Related Apoptosis-Inducing Ligand; Vacuoles

2021
A single-center retrospective safety analysis of cyclin-dependent kinase 4/6 inhibitors concurrent with radiation therapy in metastatic breast cancer patients.
    Scientific reports, 2020, 08-12, Volume: 10, Issue:1

    Topics: Aminopyridines; Breast Neoplasms; Combined Modality Therapy; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Ileitis; Molecular Targeted Therapy; Neoplasm Metastasis; Neutropenia; Outcome Assessment, Health Care; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Radiotherapy; Retrospective Studies

2020
Her2 promotes early dissemination of breast cancer by suppressing the p38-MK2-Hsp27 pathway that is targetable by Wip1 inhibition.
    Oncogene, 2020, Volume: 39, Issue:40

    Topics: Aminopyridines; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Dipeptides; Female; Heat-Shock Proteins; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase 14; Molecular Chaperones; Neoplasm Metastasis; Phosphorylation; Protein Phosphatase 2C; Protein Serine-Threonine Kinases; Pyridines; Receptor, ErbB-2; Xenograft Model Antitumor Assays

2020
Serum concentration of the CKD4/6 inhibitor abemaciclib, but not of creatinine, strongly predicts hematological adverse events in patients with breast cancer: a preliminary report.
    Investigational new drugs, 2021, Volume: 39, Issue:1

    Topics: Adult; Aged; Aminopyridines; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Creatinine; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neutrophils; Patient Acuity; Platelet Count

2021
Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
    Breast cancer (Tokyo, Japan), 2021, Volume: 28, Issue:1

    Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Retinoblastoma Binding Proteins; Ubiquitin-Protein Ligases

2021
Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 01-15, Volume: 27, Issue:2

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Fulvestrant; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Purines; Receptors, Estrogen; Thiazoles

2021
CDK4/6 Inhibition in Early-Stage Breast Cancer: The New Standard?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 12-01, Volume: 38, Issue:34

    Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Humans; Reference Standards

2020
Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3.
    The oncologist, 2021, Volume: 26, Issue:1

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Receptor, ErbB-2

2021
Cost-effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore.
    Cancer reports (Hoboken, N.J.), 2021, Volume: 4, Issue:1

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Drug Costs; Female; Follow-Up Studies; Goserelin; Humans; Kaplan-Meier Estimate; Mastectomy; Middle Aged; Multicenter Studies as Topic; Neoadjuvant Therapy; Premenopause; Progression-Free Survival; Purines; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Singapore; Survival Rate; Treatment Outcome

2021
Safety and efficacy of cyclin-dependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemia.
    Breast (Edinburgh, Scotland), 2020, Volume: 54

    Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Substitution; Female; Humans; Middle Aged; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Transaminases; Treatment Outcome

2020
Abemaciclib-induced reversible grade 4 nephrotoxicity.
    The breast journal, 2020, Volume: 26, Issue:11

    Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Female; Humans

2020
Setting the Pick: Can PI3K Inhibitors Circumvent CDK4/6 Inhibitor Resistance?
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 01-15, Volume: 27, Issue:2

    Topics: Aminopyridines; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Goserelin; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Tamoxifen; Thiazoles

2021
Real-world experience of palbociclib and ribociclib: novel oral therapy in metastatic breast cancer.
    International journal of clinical pharmacy, 2021, Volume: 43, Issue:4

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Piperazines; Purines; Pyridines; Retrospective Studies

2021
Local Targeting of Lung-Tumor-Associated Macrophages with Pulmonary Delivery of a CSF-1R Inhibitor for the Treatment of Breast Cancer Lung Metastases.
    Molecular pharmaceutics, 2020, 12-07, Volume: 17, Issue:12

    Topics: Administration, Inhalation; Administration, Intravenous; Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Lung Neoplasms; Mice; Paclitaxel; Phosphorylation; Pyrroles; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Tumor Microenvironment; Tumor-Associated Macrophages

2020
Molecular pathogenesis of breast cancer: impact of miR-99a-5p and miR-99a-3p regulation on oncogenic genes.
    Journal of human genetics, 2021, Volume: 66, Issue:5

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cell Line, Tumor; Down-Regulation; Estrogens; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Genes, Tumor Suppressor; Humans; Intracellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; MicroRNAs; Middle Aged; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nuclear Proteins; Oncogenes; Piperazines; Progesterone; Prognosis; Progression-Free Survival; Pyridines; RNA Interference; RNA, Neoplasm; RNA, Small Interfering; Treatment Outcome

2021
CDK4/6 inhibitors for HR
    Nature reviews. Clinical oncology, 2021, Volume: 18, Issue:2

    Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Humans

2021
Coronary Plaque Erosion after Abemaciclib Treatment Onset: An Unknown Side Effect?
    Thrombosis and haemostasis, 2021, Volume: 121, Issue:7

    Topics: Aged; Aminopyridines; Antineoplastic Agents; Artifacts; Benzimidazoles; Breast Neoplasms; Coronary Vessels; Enoxaparin; Female; Humans; Lipids; Myocardial Infarction; Protein Kinase Inhibitors; Thromboembolism; Ticagrelor; Treatment Outcome

2021
Hepatotoxicity associated with ribociclib among breast cancer patients.
    Acta oncologica (Stockholm, Sweden), 2021, Volume: 60, Issue:2

    Topics: Aminopyridines; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Female; Humans; Purines

2021
Complete response of leptomeningeal carcinomatosis secondary to breast cancer.
    Breast (Edinburgh, Scotland), 2020, Volume: 54

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Humans; Letrozole; Meningeal Carcinomatosis; Middle Aged; Radiotherapy, Adjuvant

2020
CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer.
    Breast (Edinburgh, Scotland), 2021, Volume: 55

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Uncertainty

2021
A quantitative systems pharmacological approach identified activation of JNK signaling pathway as a promising treatment strategy for refractory HER2 positive breast cancer.
    Journal of pharmacokinetics and pharmacodynamics, 2021, Volume: 48, Issue:2

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lapatinib; MAP Kinase Signaling System; Network Pharmacology; Protein Interaction Maps; Protein Kinase Inhibitors; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays

2021
Prognosis Varies by Intrinsic Tumor Subtype in Patients Treated with Ribociclib.
    The oncologist, 2021, Volume: 26 Suppl 2

    Topics: Aminopyridines; Breast Neoplasms; Female; Humans; Neoplasms; Prognosis; Purines

2021
Characteristics of interstitial lung disease in patients from post-marketing data on metastatic breast cancer patients who received abemaciclib in Japan.
    Breast cancer (Tokyo, Japan), 2021, Volume: 28, Issue:3

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Female; Humans; Japan; Lung Diseases, Interstitial; Middle Aged; Product Surveillance, Postmarketing; Tomography, X-Ray Computed

2021
[Locally Advanced Breast Cancer Successfully Treated with Abemaciclib and Fulvestrant-A Case Report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2020, Volume: 47, Issue:13

    Topics: Aged; Aminopyridines; Axilla; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Lymph Node Excision; Lymph Nodes; Mastectomy; Neoplasm Recurrence, Local

2020
Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer.
    Journal of comparative effectiveness research, 2021, Volume: 10, Issue:6

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Humans; Piperazines; Purines; Pyridines; Receptor, ErbB-2

2021
Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2- metastatic breast cancer.
    Breast cancer research and treatment, 2021, Volume: 188, Issue:3

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Purines; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies

2021
Ribociclib induced acute kidney injury: A case report.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021, Volume: 27, Issue:8

    Topics: Acute Kidney Injury; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Purines; Receptors, Estrogen

2021
Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib.
    Breast (Edinburgh, Scotland), 2021, Volume: 58

    Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Diarrhea; Female; Humans; Neutropenia; Receptor, ErbB-2

2021
Acute generalised exanthematous pustulosis after initiation of palbociclib therapy for metastatic breast cancer.
    The Australasian journal of dermatology, 2021, Volume: 62, Issue:3

    Topics: Aged; Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Exanthema; Female; Humans; Piperazines; Purines; Pyridines

2021
Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2- metastatic breast cancer.
    Current medical research and opinion, 2021, Volume: 37, Issue:7

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Humans; Receptor, ErbB-2; Receptors, Estrogen

2021
[A Case of Palbociclib plus Fulvestrant‒Resistant Metastatic Breast Cancer That Responded to Abemaciclib plus Fulvestrant].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2021, Volume: 48, Issue:4

    Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Piperazines; Pyridines

2021
Fatal acute hepatic failure secondary to thrombotic portal venopathy after commencing abemaciclib and fulvestrant treatment for advanced breast carcinoma: a unique autopsy finding.
    The breast journal, 2021, Volume: 27, Issue:7

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Autopsy; Benzimidazoles; Breast Neoplasms; Female; Fulvestrant; Humans; Liver Failure, Acute; Receptor, ErbB-2

2021
Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2- Advanced Breast Cancer: A Canadian Healthcare Perspective.
    PharmacoEconomics, 2021, Volume: 39, Issue:7

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Canada; Cost-Benefit Analysis; Delivery of Health Care; Female; Humans; Perimenopause; Purines; Quality-Adjusted Life Years

2021
[A Case of Hormone Receptor‒Positive HER2‒Negative Advanced/Recurrent Breast Cancer with 1.5 Years Withdrawal Period of Palbociclib Showed a Good Response Treated by Abemaciclib and Fulvestrant].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2021, Volume: 48, Issue:5

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyridines

2021
High MMP-11 expression associated with low CD8+ T cells decreases the survival rate in patients with breast cancer.
    PloS one, 2021, Volume: 16, Issue:5

    Topics: Aminopyridines; Breast Neoplasms; CD8-Positive T-Lymphocytes; Female; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Lymphocytes, Tumor-Infiltrating; Matrix Metalloproteinase 11; MCF-7 Cells; Middle Aged; Pyrazoles; Receptor, ErbB-2; Sulfonamides; Survival Analysis; Survival Rate; Tumor Microenvironment

2021
Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective.
    PharmacoEconomics, 2021, Volume: 39, Issue:9

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Canada; Cost-Benefit Analysis; Delivery of Health Care; Female; Fulvestrant; Humans; Postmenopause; Purines; Receptor, ErbB-2

2021
A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2022, Volume: 28, Issue:1

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Female; Humans; Massive Hepatic Necrosis; Middle Aged; Purines

2022
Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity.
    Cancer cell, 2021, 08-09, Volume: 39, Issue:8

    Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gain of Function Mutation; Humans; Mice, Nude; Molecular Docking Simulation; Molecular Dynamics Simulation; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Multimerization; Quinolines; Receptor, ErbB-2; Receptor, ErbB-3; Trastuzumab; Xenograft Model Antitumor Assays

2021
Efficacy and safety of palbociclib and ribociclib in patients with estrogen and/or progesterone receptor positive, HER2 receptor negative metastatic breast cancer in routine clinical practice.
    PloS one, 2021, Volume: 16, Issue:7

    Topics: Aged; Aminopyridines; Breast Neoplasms; Databases, Factual; Disease-Free Survival; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Piperazines; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate

2021
MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 11-01, Volume: 27, Issue:21

    Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Benzimidazoles; Breast Neoplasms; Drug Combinations; Female; Fulvestrant; Humans; Neoplasm Staging; Progression-Free Survival; Receptor, ErbB-2; Treatment Outcome

2021
A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 11-01, Volume: 27, Issue:21

    Topics: Adult; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Purines; Receptors, Estrogen; Thiazoles; Thiophenes

2021
FDA approves Novartis's CDK4/6 inhibitor.
    Nature reviews. Drug discovery, 2017, 03-30, Volume: 16, Issue:4

    Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Approval; Drug Industry; Female; Humans; Purines; United States; United States Food and Drug Administration

2017
Ribociclib: First Global Approval.
    Drugs, 2017, Volume: 77, Issue:7

    Topics: Administration, Oral; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Approval; Enzyme Inhibitors; Female; Humans; Purines; United States; United States Food and Drug Administration

2017
Astex shapes CDK4/6 inhibitor for approval.
    Nature biotechnology, 2017, 05-09, Volume: 35, Issue:5

    Topics: Aminopyridines; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Approval; Drug Industry; Female; Humans; Purines; United States; United States Food and Drug Administration

2017
Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Breast Cancer: More Breakthroughs and an Embarrassment of Riches.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, 09-01, Volume: 35, Issue:25

    Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Embarrassment; Female; Fulvestrant; Humans

2017
Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate.
    Bioorganic & medicinal chemistry letters, 2017, 08-01, Volume: 27, Issue:15

    Topics: Aminopyridines; Anilides; Animals; Antineoplastic Agents; Apoptosis; Breast; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase 9; Drug Screening Assays, Antitumor; Female; Humans; Lung; Lung Neoplasms; Mice; Mice, Inbred BALB C; Molecular Docking Simulation; Protein Kinase Inhibitors; Purines; Pyridines

2017
Informed Consent and Decision Making Among Participants in Novel-Design Phase I Oncology Trials.
    Journal of oncology practice, 2017, Volume: 13, Issue:10

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase I as Topic; Decision Making; Female; Humans; Informed Consent; Morpholines; Motivation; Neoplasm Metastasis; Protein Kinase Inhibitors; Qualitative Research; Research Subjects

2017
Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 08-01, Volume: 28, Issue:8

    Topics: Aminopyridines; Breast Neoplasms; Female; Humans; Molecular Targeted Therapy; Purines; Translational Research, Biomedical

2017
Ribociclib (Kisqali) for advanced or metastatic breast cancer.
    The Medical letter on drugs and therapeutics, 2017, 10-23, Volume: 59, Issue:1532

    Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Neoplasm Metastasis; Protein Kinase Inhibitors; Purines; Signal Transduction; Treatment Outcome

2017
Abemaciclib (Verzenio)--a third CDK 4/6 inhibitor for breast cancer.
    The Medical letter on drugs and therapeutics, 2017, 11-06, Volume: 59, Issue:1533

    Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Protein Kinase Inhibitors; Signal Transduction; Treatment Outcome

2017
NICE recommends routine NHS funding for new breast cancer drugs.
    BMJ (Clinical research ed.), 2017, 11-15, Volume: 359

    Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Drug Costs; Female; Humans; Piperazines; Purines; Pyridines; State Medicine; United Kingdom

2017
Efficacy of buparlisib in treating breast cancer.
    Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:18

    Topics: Aminopyridines; Breast Neoplasms; Clinical Trials as Topic; Female; Half-Life; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; TOR Serine-Threonine Kinases

2017
A2B adenosine receptor agonist induces cell cycle arrest and apoptosis in breast cancer stem cells via ERK1/2 phosphorylation.
    Cellular oncology (Dordrecht), 2018, Volume: 41, Issue:1

    Topics: Adenosine A2 Receptor Agonists; Aminopyridines; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Female; Humans; MCF-7 Cells; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplastic Stem Cells; Phosphorylation; Receptor, Adenosine A2B

2018
Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 03-01, Volume: 29, Issue:3

    Topics: Aged; Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Genotype; Humans; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Retinoblastoma Binding Proteins; Ubiquitin-Protein Ligases

2018
Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer.
    Expert opinion on pharmacotherapy, 2018, Volume: 19, Issue:3

    Topics: Aminopyridines; Breast Neoplasms; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estrogen Receptor alpha; Female; Half-Life; Humans; Neoplasm Staging; Purines; Receptor, ErbB-2; T-Lymphocytes; Treatment Outcome

2018
FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2018, 07-01, Volume: 24, Issue:13

    Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Approval; Female; Humans; Neoplasm Metastasis; Neoplasm Staging; Postmenopause; Protein Kinase Inhibitors; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Research Design; Treatment Outcome

2018
Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2018, 07-01, Volume: 24, Issue:13

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Humans; Postmenopause; Purines

2018
[CDK4/6 inhibitors: biomarkers, mechanisms of resistance and interest of the study of the circulating tumor DNA].
    Bulletin du cancer, 2018, Volume: 105, Issue:6

    Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Biomarkers, Tumor; Breast Neoplasms; Circulating Tumor DNA; Class I Phosphatidylinositol 3-Kinases; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Mutation; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Retinoblastoma Binding Proteins; Ubiquitin-Protein Ligases

2018
Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
    Journal of managed care & specialty pharmacy, 2018, Volume: 24, Issue:6

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Letrozole; Models, Biological; Models, Economic; Nitriles; Piperazines; Postmenopause; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Treatment Outcome; Triazoles; United States

2018
Ribociclib in premenopausal women with advanced breast cancer.
    The Lancet. Oncology, 2018, Volume: 19, Issue:7

    Topics: Aminopyridines; Breast; Breast Neoplasms; Female; Humans; Purines

2018
Expanding ribociclib use.
    Nature reviews. Clinical oncology, 2018, Volume: 15, Issue:8

    Topics: Aminopyridines; Breast; Breast Neoplasms; Female; Humans; Purines

2018
Radiation-induced morphea-a rare but severe late effect of adjuvant breast irradiation : Case report and review of the literature.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2018, Volume: 194, Issue:11

    Topics: Aged; Aminopyridines; Anastrozole; Benzimidazoles; Biopsy; Breast; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Mastectomy, Segmental; Neoadjuvant Therapy; Neoplasm Staging; Radiation Injuries; Radiotherapy, Adjuvant; Scleroderma, Localized

2018
Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
    Current medical research and opinion, 2018, Volume: 34, Issue:12

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Budgets; Female; Humans; Letrozole; Postmenopause; Purines; Receptor, ErbB-2; Receptors, Estrogen; United States

2018
Ribociclib plus letrozole and concomitant palliative radiotherapy for metastatic breast cancer.
    Breast (Edinburgh, Scotland), 2018, Volume: 42

    Topics: Adult; Aged; Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Italy; Middle Aged; Palliative Care; Purines; Radiotherapy, Adjuvant

2018
Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2- Breast Cancer.
    Oncology (Williston Park, N.Y.), 2018, Oct-15, Volume: 32, Issue:10

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Carcinoma, Lobular; Colonic Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone

2018
Ribociclib in hormone-receptor-positive advanced breast cancer: Establishing a value-based cost in China.
    Breast (Edinburgh, Scotland), 2019, Volume: 43

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; China; Cost-Benefit Analysis; Drug Costs; Female; Humans; Letrozole; Progression-Free Survival; Purines; Quality-Adjusted Life Years; Receptors, Estrogen; Receptors, Progesterone

2019
PI3K: A master regulator of brain metastasis-promoting macrophages/microglia.
    Glia, 2018, Volume: 66, Issue:11

    Topics: Adult; Aged; Aminopyridines; Animals; Brain Neoplasms; Breast Neoplasms; Calcium-Binding Proteins; Disease Models, Animal; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Glial Fibrillary Acidic Protein; Humans; Macrophages; Mice; Mice, Inbred BALB C; Microfilament Proteins; Microglia; Middle Aged; Morpholines; Phosphatidylinositol 3-Kinases; Signal Transduction; TOR Serine-Threonine Kinases

2018
Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate.
    Clinical pharmacology and therapeutics, 2019, Volume: 105, Issue:5

    Topics: Aminopyridines; Antineoplastic Agents, Immunological; Benzimidazoles; Biological Transport; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Glomerular Filtration Rate; Humans; Hypoglycemic Agents; Kidney Tubules; Metabolic Clearance Rate; Metformin; Organic Cation Transport Proteins; Organic Cation Transporter 2

2019
Why upfront use of CDK inhibitors for the treatment of advanced breast cancer may be wasteful, and how we can increase their value.
    Breast (Edinburgh, Scotland), 2019, Volume: 43

    Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Benzimidazoles; Breast Neoplasms; Cost-Benefit Analysis; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Costs; Female; Humans; Neutropenia; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptors, Estrogen; Receptors, Progesterone

2019
PI3K inhibitor provides durable response in metastatic metaplastic carcinoma of the breast: A hidden gem in the BELLE-4 study.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2019, Volume: 118, Issue:9

    Topics: Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Female; Humans; Metaplasia; Morpholines; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Randomized Controlled Trials as Topic; Tomography, X-Ray Computed; Treatment Outcome

2019
Pharmacological inhibition of the IKKε/TBK-1 axis potentiates the anti-tumour and anti-metastatic effects of Docetaxel in mouse models of breast cancer.
    Cancer letters, 2019, 05-28, Volume: 450

    Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Synergism; Female; Humans; I-kappa B Kinase; Mammary Neoplasms, Experimental; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Serine-Threonine Kinases; RAW 264.7 Cells

2019
Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
    Breast cancer research and treatment, 2019, Volume: 175, Issue:3

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Letrozole; Markov Chains; Models, Economic; Piperazines; Purines; Pyridines; Quality of Life; Receptor, ErbB-2; Survival Analysis; Treatment Outcome

2019
Micellar Formulation of Talazoparib and Buparlisib for Enhanced DNA Damage in Breast Cancer Chemoradiotherapy.
    ACS applied materials & interfaces, 2019, Apr-03, Volume: 11, Issue:13

    Topics: Aminopyridines; Animals; Breast Neoplasms; Cell Line, Tumor; Chemoradiotherapy; DNA Damage; Female; Humans; Mice; Mice, Inbred BALB C; Micelles; Morpholines; Phthalazines; Xenograft Model Antitumor Assays

2019
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.
    Nature communications, 2019, 03-26, Volume: 10, Issue:1

    Topics: Aminopyridines; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Circulating Tumor DNA; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Female; Fulvestrant; High-Throughput Nucleotide Sequencing; Humans; MCF-7 Cells; Mice; Mutation; Naphthalenes; Piperazines; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridines; Quinolines; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Receptors, Estrogen; Signal Transduction; Xenograft Model Antitumor Assays

2019
Patients' preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan.
    Breast cancer (Tokyo, Japan), 2019, Volume: 26, Issue:5

    Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Diarrhea; Female; Fulvestrant; Humans; Japan; Middle Aged; Patient Preference; Postmenopause; Progression-Free Survival; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Socioeconomic Factors; Surveys and Questionnaires

2019
Concurrent radiotherapy with palbociclib or ribociclib for metastatic breast cancer patients: Preliminary assessment of toxicity.
    Breast (Edinburgh, Scotland), 2019, Volume: 46

    Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Chemoradiotherapy; ErbB Receptors; Female; Humans; Middle Aged; Neutropenia; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Radiation Dosage; Treatment Outcome

2019
Different sensitivities of senescent breast cancer cells to immune cell-mediated cytotoxicity.
    Cancer science, 2019, Volume: 110, Issue:9

    Topics: Aminopyridines; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Benzimidazoles; Breast Neoplasms; CD4-Positive T-Lymphocytes; Cell Line, Tumor; Cellular Senescence; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Doxorubicin; Drug Screening Assays, Antitumor; Female; Humans; Killer Cells, Natural; Molecular Targeted Therapy; Neoplasm Recurrence, Local

2019
Ribociclib Causing Transient Glanzmann Thrombasthenia-like Picture: A Report of 4 Cases.
    Clinical breast cancer, 2019, Volume: 19, Issue:5

    Topics: Aminopyridines; Blood Platelet Disorders; Breast Neoplasms; Female; Humans; Middle Aged; Postmenopause; Protein Kinase Inhibitors; Purines

2019
Achieving Improved Survival Outcomes in Advanced Breast Cancer.
    The New England journal of medicine, 2019, 07-25, Volume: 381, Issue:4

    Topics: Aminopyridines; Breast; Breast Neoplasms; Humans; Purines

2019
Quantification of Economic Impact of Drug Wastage in Oral Oncology Medications: Comparison of 3 Methods Using Palbociclib and Ribociclib in Advanced or Metastatic Breast Cancer.
    Journal of managed care & specialty pharmacy, 2019, Volume: 25, Issue:8

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Drug Costs; Drug Utilization; Evaluation Studies as Topic; Female; Health Care Costs; Humans; Middle Aged; Models, Economic; Piperazines; Purines; Pyridines; Randomized Controlled Trials as Topic; Retrospective Studies

2019
Small-molecule inhibitor BMS-777607 induces breast cancer cell polyploidy with increased resistance to cytotoxic chemotherapy agents.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:5

    Topics: Aminopyridines; Aurora Kinase B; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromosome Aberrations; Drug Resistance, Neoplasm; Female; Histones; Humans; Phosphorylation; Polyploidy; Protein Kinase Inhibitors; Pyridones; Receptor Protein-Tyrosine Kinases; Spindle Apparatus

2013
RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.
    The Journal of clinical investigation, 2013, Volume: 123, Issue:6

    Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; MCF-7 Cells; Mice; Mice, Nude; Molecular Targeted Therapy; Morpholines; Open Reading Frames; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinolines; Ribosomal Protein S6 Kinases, 90-kDa; Signal Transduction; Transcriptome; Tumor Burden; Xenograft Model Antitumor Assays

2013
Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Molecular cancer research : MCR, 2013, Volume: 11, Issue:10

    Topics: Aminopyridines; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromones; Everolimus; Female; Humans; Imidazoles; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolines; Signal Transduction; Sirolimus; Tamoxifen; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2013
The gene dosage of class Ia PI3K dictates the development of PTEN hamartoma tumor syndrome.
    Cell cycle (Georgetown, Tex.), 2013, Dec-01, Volume: 12, Issue:23

    Topics: Alleles; Aminopyridines; Animals; Breast Neoplasms; Class Ia Phosphatidylinositol 3-Kinase; Disease Models, Animal; Female; Gene Dosage; Genotype; Hamartoma Syndrome, Multiple; Mice; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Skin Neoplasms

2013
Prevention of BMS-777607-induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics.
    Molecular oncology, 2014, Volume: 8, Issue:3

    Topics: Aging; Aminopyridines; Breast; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Morpholines; Polyploidy; Protein Kinase Inhibitors; Pyridones; Signal Transduction; TOR Serine-Threonine Kinases

2014
Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.
    Breast cancer research : BCR, 2014, Jan-23, Volume: 16, Issue:1

    Topics: Aminopyridines; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Mice; Mice, Nude; Morpholines; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays

2014
Synthesis, characterization, and evaluation of cis-diphenyl pyridineamine platinum(II) complexes as potential anti-breast cancer agents.
    Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry, 2014, Volume: 19, Issue:6

    Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Cell Survival; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; MCF-7 Cells; Models, Molecular; Molecular Structure; Organoplatinum Compounds; Structure-Activity Relationship; Tumor Cells, Cultured

2014
Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition.
    Oncotarget, 2014, Jul-30, Volume: 5, Issue:14

    Topics: Aminopyridines; Apoptosis; Breast Neoplasms; DNA-Binding Proteins; Female; Gene Knockdown Techniques; Heterocyclic Compounds, 3-Ring; Humans; MCF-7 Cells; Morpholines; Nuclear Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases, 70-kDa; RNA, Small Interfering; Signal Transduction; Transcription Factors; Transfection

2014
Cell cycle inhibitors make progress.
    Journal of the National Cancer Institute, 2014, Volume: 106, Issue:7

    Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cell Cycle; Clinical Trials, Phase I as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Piperazines; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Purines; Pyridines; Randomized Controlled Trials as Topic; ras Proteins; Receptors, Estrogen

2014
MEL-18 loss mediates estrogen receptor-α downregulation and hormone independence.
    The Journal of clinical investigation, 2015, Volume: 125, Issue:5

    Topics: Aminopyridines; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Cysteine Endopeptidases; Drug Resistance, Neoplasm; Endopeptidases; Estrogen Receptor alpha; Estrogens; Female; Humans; Kaplan-Meier Estimate; Mice; Morpholines; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Polycomb Repressive Complex 1; Progesterone; Proportional Hazards Models; Proteasome Endopeptidase Complex; Protein Processing, Post-Translational; Receptor, ErbB-2; Receptors, Progesterone; RNA, Messenger; RNA, Neoplasm; Sp1 Transcription Factor; Sumoylation; Tamoxifen; Triple Negative Breast Neoplasms; Tumor Suppressor Protein p53

2015
β-Adrenergic receptors suppress Rap1B prenylation and promote the metastatic phenotype in breast cancer cells.
    Cancer biology & therapy, 2015, Volume: 16, Issue:9

    Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Antagonists; Aminopyridines; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Membrane; Cell Movement; Female; GTP-Binding Protein alpha Subunits, Gs; Humans; Isoproterenol; Neoplasm Metastasis; Phenotype; Phosphorylation; Propranolol; Protein Prenylation; Protein Transport; rap GTP-Binding Proteins; Receptors, Adrenergic, beta; Signal Transduction

2015
Inhibition of cyclin-dependent kinases 4 and 6 in breast cancer.
    Clinical advances in hematology & oncology : H&O, 2015, Volume: 13, Issue:4

    Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Clinical Trials, Phase II as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptors, Estrogen; Research; Treatment Outcome

2015
Molecular diagnostics for precision medicine in breast cancer treatment: what does the future hold?
    Breast cancer (Tokyo, Japan), 2016, Volume: 23, Issue:1

    Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estradiol; Everolimus; Female; Fulvestrant; Humans; Molecular Targeted Therapy; Pathology, Molecular; Piperazines; Precision Medicine; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; TOR Serine-Threonine Kinases; Trastuzumab

2016
A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Apr-01, Volume: 22, Issue:7

    Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Morpholines; Neoplasm Metastasis; Phosphoinositide-3 Kinase Inhibitors; Postmenopause; PTEN Phosphohydrolase; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome

2016
Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells.
    Cell death & disease, 2015, Dec-17, Volume: 6

    Topics: Aminopyridines; Animals; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Nude; Morpholines; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Signal Transduction

2015
PI3K Inhibitor Improves PFS in BELLE-2 Trial.
    Cancer discovery, 2016, Volume: 6, Issue:2

    Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Congresses as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Morpholines; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Treatment Outcome

2016
Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3.
    Oncotarget, 2016, Mar-22, Volume: 7, Issue:12

    Topics: Aminopyridines; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Proliferation; Dipeptides; DNA Damage; Drug Resistance, Neoplasm; Female; Humans; Imidazoles; Piperazines; Protein Phosphatase 2C; Proto-Oncogene Proteins c-mdm2; Tumor Cells, Cultured; Tumor Suppressor Protein p53

2016
New p32/gC1qR Ligands for Targeted Tumor Drug Delivery.
    Chembiochem : a European journal of chemical biology, 2016, Apr-01, Volume: 17, Issue:7

    Topics: Aminopyridines; Animals; Antineoplastic Agents; Breast Neoplasms; Carrier Proteins; Cell Line, Tumor; Drug Delivery Systems; Ethylenediamines; Female; Humans; Ligands; Mice; Mitochondrial Proteins; Nanoparticles; Peptides, Cyclic

2016
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.
    Cancer discovery, 2016, Volume: 6, Issue:7

    Topics: Aminopyridines; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease Models, Animal; Drug Monitoring; Female; Humans; Lung Neoplasms; Male; Mice; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Xenograft Model Antitumor Assays

2016
Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases.
    Nature medicine, 2016, Volume: 22, Issue:7

    Topics: Adaptor Proteins, Signal Transducing; Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Breast Neoplasms; Carrier Proteins; Caspase 3; Cell Cycle Proteins; DNA Repair; Drug Resistance, Neoplasm; Drug Therapy, Combination; Eukaryotic Initiation Factors; Everolimus; Female; Gene Expression Profiling; Genomic Instability; Humans; Immunohistochemistry; Ki-67 Antigen; Magnetic Resonance Imaging; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, SCID; Molecular Targeted Therapy; Morpholines; Multiprotein Complexes; Neoplasm Transplantation; Phosphoinositide-3 Kinase Inhibitors; Phosphoproteins; Phosphorylation; Receptor, ErbB-2; Remission Induction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2016
Single-Agent Abemaciclib Active in Breast Cancer.
    Cancer discovery, 2016, Volume: 6, Issue:8

    Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Clinical Trials, Phase II as Topic; Disease-Free Survival; Female; Humans; Neoplasm Metastasis; Survival Analysis; Treatment Outcome

2016
CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer.
    Cancer discovery, 2016, Volume: 6, Issue:7

    Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Male; Neoplasms; Treatment Outcome

2016
Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:11

    Topics: Aminopyridines; Animals; Antibodies; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Humans; Lapatinib; Mice; Morpholines; ortho-Aminobenzoates; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; PTEN Phosphohydrolase; Pyrimidinones; Quinazolines; Receptor, ErbB-2; Thiazoles; Xenograft Model Antitumor Assays

2016
Ribociclib in HR-positive, HER2-negative breast cancer.
    The Lancet. Oncology, 2016, Volume: 17, Issue:11

    Topics: Aminopyridines; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Protein Kinase Inhibitors; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome

2016
Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence.
    Oncogene, 2017, 04-20, Volume: 36, Issue:16

    Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Female; Gene Amplification; Humans; MCF-7 Cells; Protein Kinase Inhibitors; Receptors, Estrogen; Signal Transduction

2017
Ribociclib Lengthens Breast Cancer Survival.
    Cancer discovery, 2016, Volume: 6, Issue:12

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Purines; Treatment Outcome; Triazoles

2016
Abemaciclib Shows Promise for Early Breast Cancer.
    Cancer discovery, 2017, Volume: 7, Issue:2

    Topics: Aminopyridines; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Clinical Trials, Phase II as Topic; Disease-Free Survival; Female; Humans; Ki-67 Antigen; Nitriles; Receptor, ErbB-2; Survival Analysis; Treatment Outcome; Triazoles

2017
Benefit Mixed with Caution for Buparlisib.
    Cancer discovery, 2017, Volume: 7, Issue:2

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Morpholines; Postmenopause; Protein Kinase Inhibitors; Survival Analysis; Treatment Outcome

2017
Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells.
    Oncotarget, 2017, Jan-24, Volume: 8, Issue:4

    Topics: 14-3-3 Proteins; Active Transport, Cell Nucleus; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Cytoplasm; Dose-Response Relationship, Drug; Female; Forkhead Box Protein O3; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Hydroxychloroquine; Morpholines; Mutation; Protein Kinase Inhibitors; RNA Interference; Signal Transduction; Time Factors; Transfection; Uterine Cervical Neoplasms

2017
[Cell cycle inhibitors in endocrine receptor positive breast cancer].
    Bulletin du cancer, 2017, Volume: 104, Issue:2

    Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cell Cycle; Cell Cycle Checkpoints; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Neoplasms, Hormone-Dependent; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines

2017
Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.
    Cancer research, 2017, 05-01, Volume: 77, Issue:9

    Topics: Aminopyridines; Animals; Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Indazoles; MCF-7 Cells; Mice; Phosphatidylinositol 3-Kinases; Piperazines; Protein Serine-Threonine Kinases; Purines; Pyridines; Pyrimidines; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Receptors, Estrogen; Xenograft Model Antitumor Assays

2017
Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models.
    Cancer biology & therapy, 2010, May-15, Volume: 9, Issue:10

    Topics: Administration, Oral; Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Crk-Associated Substrate Protein; Female; Focal Adhesion Protein-Tyrosine Kinases; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Phosphorylation; Tyrosine; Xenograft Model Antitumor Assays

2010
New evidence in pulmonary and preventive medicine.
    Internal and emergency medicine, 2010, Volume: 5, Issue:2

    Topics: Adrenergic beta-Agonists; Albuterol; Aminopyridines; Benzamides; Breast Neoplasms; Bronchodilator Agents; Cyclopropanes; Disease Progression; Early Detection of Cancer; Evidence-Based Medicine; Female; Humans; Papillomavirus Vaccines; Preventive Medicine; Primary Prevention; Pulmonary Disease, Chronic Obstructive; Salmeterol Xinafoate; Scopolamine Derivatives; Secondary Prevention; Tiotropium Bromide; Uterine Cervical Neoplasms

2010
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
    Breast cancer research : BCR, 2011, Mar-01, Volume: 13, Issue:2

    Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Estradiol; Estrogens; Everolimus; Female; Fulvestrant; Humans; Imidazoles; Morpholines; Mutation; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; PTEN Phosphohydrolase; Quinolines; Receptors, Estrogen; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases

2011
Discovery of new aminopyrimidine-based phosphoinositide 3-kinase beta (PI3Kβ) inhibitors with selectivity over PI3Kα.
    Bioorganic & medicinal chemistry letters, 2011, Dec-01, Volume: 21, Issue:23

    Topics: Aminopyridines; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Drug Discovery; Enzyme Activation; Enzyme Inhibitors; Female; Humans; Hydrogen Bonding; Inhibitory Concentration 50; Models, Molecular; Molecular Structure; Morpholines; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Isoforms; Pyrimidinones; Substrate Specificity

2011
Adhesion and migration of extracellular matrix-stimulated breast cancer.
    The Journal of surgical research, 2003, Volume: 110, Issue:1

    Topics: Acetates; Aminopyridines; Antibodies, Monoclonal; Benzodiazepinones; Breast Neoplasms; Cell Adhesion; Cell Movement; Extracellular Matrix; Female; Fibronectins; Humans; Integrin alphaVbeta3; Integrin beta Chains; Integrins; Peptide Fragments; Receptors, Vitronectin; Tumor Cells, Cultured; Vitronectin

2003